[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 268
1. Chou CH, Lieu AS, Wu CH, Chang LK, Loh JK, Lin RC, Chen WJ, Liao HD, Fu WS, Chang CS, Lin CC, Hsu CM, Chio CC, Howng SL, Hong YR: Differential expression of hedgehog signaling components and Snail/E-cadherin in human brain tumors. Oncol Rep; 2010 Nov;24(5):1225-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential expression of hedgehog signaling components and Snail/E-cadherin in human brain tumors.
  • However, the role of Hh signaling components and Snail/E-cadherin in brain tumors is not yet fully understood.
  • We analyzed the expression of Hh signaling components and Snail/E-cadherin in 69 brain tumors by reverse transcription-polymerase chain reaction (RT-PCR).
  • The data showed that overexpression of Smo (35/69), Ptch (50/69), Gli1 (56/69), Gli2 (29/69) and N-myc (39/69) might contribute to brain tumorigenesis.
  • Our results also indicated that Snail and E-cadherin showed opposing expression in malignant tumors (high grade astrocytoma and metastasis).
  • Snail and E-cadherin showed less correlation in benign brain tumors.
  • Taken together, our results demonstrate that Hh signaling components, the expression and mutations of Snail and the expression of E-cadherin may play an important role in human brain tumorigenesis.
  • [MeSH-major] Brain Neoplasms / genetics. Cadherins / genetics. Hedgehog Proteins / genetics. Transcription Factors / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20878114.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cadherins; 0 / Hedgehog Proteins; 0 / Transcription Factors; 0 / snail family transcription factors
  •  go-up   go-down


2. Lönnrot K, Terho M, Kähärä V, Haapasalo H, Helén P: Desmoplastic infantile ganglioglioma: novel aspects in clinical presentation and genetics. Surg Neurol; 2007 Sep;68(3):304-8; discussion 308
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Desmoplastic infantile ganglioglioma is a rare tumor occurring mainly in infants and young children.
  • Both radiological and histopathological appearances may resemble malignancy, although its clinical course is mainly benign.
  • METHODS: Altogether, 5 cases of DIG have been operated on in our hospital since the first diagnosis of DIG in Finland in 1993.
  • In 4 cases, there was a histopathologically verified single cystic tumor.
  • There were no recurrences in any of the patients after tumor resection.
  • For the first time, we describe EGFR and MYCN amplifications in tumors which are, respectively, of their mixed glial and neuronal origin.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / etiology. Ganglioglioma / diagnosis. Ganglioglioma / etiology
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. Epilepsy / etiology. Follow-Up Studies. Humans. Male. Neoplasm Proteins / metabolism. Nerve Tissue Proteins / metabolism. Oncogenes / physiology. Retrospective Studies. Treatment Outcome


3. Comtesse N, Zippel A, Walle S, Monz D, Backes C, Fischer U, Mayer J, Ludwig N, Hildebrandt A, Keller A, Steudel WI, Lenhof HP, Meese E: Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets. Proc Natl Acad Sci U S A; 2005 Jul 5;102(27):9601-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complex humoral immune response against a benign tumor: frequent antibody response against specific antigens as diagnostic targets.
  • There are numerous studies on the immune response against malignant human tumors.
  • This study was aimed to address the complexity and specificity of humoral immune response against a benign human tumor.
  • We assembled a panel of 62 meningioma-expressed antigens that show reactivity with serum antibodies of meningioma patients, including 41 previously uncharacterized antigens by screening of a fetal brain expression library.
  • We detected 17 antigens exclusively with patient sera, including 12 sera that were reactive against KIAA1344, 9 against natural killer tumor recognition (NKTR), and 7 against SRY (sex determining region Y)-box2 (SOX2).
  • Our results show a highly complex but specific humoral immune response against a benign tumor with a distinct serum reactivity pattern and a decline of complexity with malignancy.
  • [MeSH-major] Antibodies, Neoplasm / blood. Antibody Formation / immunology. Antigens, Neoplasm / immunology. Meningioma / immunology
  • [MeSH-minor] Antibody Specificity. Brain / metabolism. DNA Primers. Discriminant Analysis. Gene Library. Humans. Meninges / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Sequence Analysis, DNA. Serologic Tests

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3560-8 [10589772.001]
  • [Cites] J Exp Med. 1999 Sep 20;190(6):815-26 [10499920.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Biochem Biophys Res Commun. 2001 May 11;283(3):634-40 [11341771.001]
  • [Cites] Cytogenet Cell Genet. 2001;93(3-4):207-20 [11528114.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Jan 18;290(2):830-8 [11785977.001]
  • [Cites] Oncogene. 2002 Jan 10;21(2):239-47 [11803467.001]
  • [Cites] Semin Cancer Biol. 2002 Feb;12(1):25-31 [11926408.001]
  • [Cites] Nat Immunol. 2002 Nov;3(11):999-1005 [12407407.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):73-84 [12532422.001]
  • [Cites] Cancer Immun. 2001 Mar 30;1:4 [12747765.001]
  • [Cites] J Immunol. 2003 Dec 1;171(11):5956-63 [14634107.001]
  • [Cites] Int J Oncol. 2004 Feb;24(2):257-63 [14719100.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1420-7 [14691456.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):51-60 [15305375.001]
  • [Cites] Hum Genet. 1987 Dec;77(4):349-51 [2891603.001]
  • [Cites] Cancer Res. 1990 Sep 15;50(18):5863-7 [2393856.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):542-6 [8421688.001]
  • [Cites] Biochem Biophys Res Commun. 1993 Sep 15;195(2):686-96 [8373407.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Am J Pathol. 1995 Apr;146(4):827-32 [7717450.001]
  • [Cites] Cancer Res. 1995 Oct 15;55(20):4696-701 [7553651.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] Mol Biol Cell. 1996 Jul;7(7):1015-24 [8862517.001]
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] J Biol Chem. 1997 Jul 18;272(29):17907-11 [9218414.001]
  • [Cites] Hum Mol Genet. 1997 Nov;6(12):2031-41 [9356211.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Hum Mol Genet. 1998 Nov;7(12):1859-72 [9811929.001]
  • [Cites] Nucleic Acids Res. 1999 Mar 15;27(6):1409-20 [10037800.001]
  • [Cites] Blood. 1999 Apr 1;93(7):2158-66 [10090922.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4198-203 [10760287.001]
  • (PMID = 15983380.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Neoplasm; 0 / Antigens, Neoplasm; 0 / DNA Primers
  • [Other-IDs] NLM/ PMC1172238
  •  go-up   go-down


Advertisement
4. McCarthy BJ, Kruchko C, Central Brain Tumor Registry of the United States: Consensus conference on cancer registration of brain and central nervous system tumors. Neuro Oncol; 2005 Apr;7(2):196-201
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Consensus conference on cancer registration of brain and central nervous system tumors.
  • The passage of Public Law 107-260, the Benign Brain Tumor Cancer Registries Amendment Act, in October 2002 has made the collection of all primary brain tumors a reality.
  • However, at the first Consensus Conference on Brain Tumor Definition for Registration in 2002, and during the development of training materials for benign brain tumor collection, several issues were identified that were tabled for future discussion.
  • These and other issues were addressed at the subsequent 2003 Consensus Conference on Cancer Registration of Brain and Central Nervous System Tumors, at which the Central Brain Tumor Registry of the United States facilitated a discussion among epidemiologists, neurosurgeons, and neuropathologists.
  • (1) amend the histology coding scheme for cysts and tumor-like lesions that currently have a code in the third edition of the International Classification of Disease for Oncology (ICDO), (2) collect data on all instances of specific cysts and tumor-like lesions that are located in brain and other CNS sites but currently lack ICDO codes, (3) establish a new ICDO topography site for skull base tumors for the brain and CNS, and (4) collect data on genetic syndromes in patients diagnosed with brain or CNS tumors.
  • Because classification of primary intracranial and other CNS tumors is dynamic, and the registration and coding of these tumors will need to be periodically reviewed.
  • [MeSH-major] Central Nervous System Neoplasms / classification. Central Nervous System Neoplasms / pathology. Registries

  • Genetic Alliance. consumer health - Brain Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 1998 Jul 15;90(14):1039-71 [9672254.001]
  • [Cites] Neuro Oncol. 2002 Apr;4(2):134-45 [11916506.001]
  • (PMID = 15831238.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Consensus Development Conference; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 13
  • [Other-IDs] NLM/ PMC1871892
  •  go-up   go-down


5. McCarthy BJ, Schellinger KA, Propp JM, Kruchko C, Malmer B: A case for the worldwide collection of primary benign brain tumors. Neuroepidemiology; 2009;33(3):268-75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case for the worldwide collection of primary benign brain tumors.
  • BACKGROUND: Incidence data on malignant tumors are reported by the International Agency for Research on Cancer, with 189,485 new malignant brain tumors globally in 2002.
  • However, collection and reporting of benign brain tumors are not universal.
  • The objective here is to encourage the collection of primary benign brain tumors worldwide.
  • METHODS: Worldwide numbers of primary benign brain tumors were estimated through published articles and cancer registry reports presenting directly or indirectly reported benign incidence rates or frequencies for regions or countries.
  • RESULTS: An estimated 186,678 benign brain tumors were diagnosed worldwide in 2002.
  • The estimated numbers of benign brain tumors were higher in females than males (105,918 vs. 80,759).
  • Since many countries do not report primary benign brain tumors, the incidence rate estimates vary significantly by region.
  • CONCLUSIONS: This is the first survey to assess worldwide numbers of benign brain tumors.
  • However, the estimated number of benign brain tumors approximately equals, and could exceed, the number of malignant brain tumors globally.
  • Registration of primary benign brain histologies in different geographical areas and ethnicities could provide clues to the underlying causes of these tumors.
  • [MeSH-major] Brain Neoplasms / epidemiology. Global Health


6. Morikawa M, Demura Y, Mizuno S, Ameshima S, Ishizaki T, Okazawa H: FDG positron emission tomography imaging of drug-induced pneumonitis. Ann Nucl Med; 2008 May;22(4):335-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Several studies have reported the findings of fluorine-18-labeled fluoro-2-deoxy-D: -glucose positron emission tomography (FDG-PET) in benign lung disease with diffuse pulmonary injury; however, the characteristics and effectiveness of FDG-PET imaging for interstitial pneumonitis have not been substantiated.
  • [MeSH-minor] Aged. Anxiety Disorders / drug therapy. Anxiety Disorders / etiology. Brain Neoplasms / complications. Brain Neoplasms / secondary. Breast Neoplasms / pathology. Breast Neoplasms / surgery. Dibenzothiazepines / adverse effects. Dibenzothiazepines / therapeutic use. Female. Humans. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Paclitaxel / adverse effects. Paclitaxel / therapeutic use. Positron-Emission Tomography. Quetiapine Fumarate. Sensitivity and Specificity. Tomography, X-Ray Computed. Whole Body Imaging

  • MedlinePlus Health Information. consumer health - Pneumonia.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18535887.001).
  • [ISSN] 0914-7187
  • [Journal-full-title] Annals of nuclear medicine
  • [ISO-abbreviation] Ann Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Dibenzothiazepines; 0Z5B2CJX4D / Fluorodeoxyglucose F18; 2S3PL1B6UJ / Quetiapine Fumarate; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


7. Marshall AE, Martin SE, Agaram NP, Chen JH, Horn EM, Douglas-Akinwande AC, Hattab EM: A 61-year-old woman with osteomalacia and a thoracic spine lesion. Brain Pathol; 2010 Mar;20(2):499-502
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Phosphaturic mesenchymal tumor, mixed connective tissue variant (PMT-MCT) is a rare, largely benign, mesenchymal neoplasm almost invariably associated with oncogenic osteomalacia.
  • [MeSH-major] Osteomalacia / diagnosis. Osteomalacia / pathology. Spinal Neoplasms / diagnosis. Spinal Neoplasms / pathology. Thoracic Vertebrae
  • [MeSH-minor] Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasms, Complex and Mixed / complications. Neoplasms, Complex and Mixed / diagnosis. Neoplasms, Complex and Mixed / pathology. Neoplasms, Connective Tissue / complications. Neoplasms, Connective Tissue / diagnosis. Neoplasms, Connective Tissue / pathology

  • Genetic Alliance. consumer health - Osteomalacia.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20438469.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Switzerland
  •  go-up   go-down


8. Monaco E 3rd, Kondziolka D, Mongia S, Niranjan A, Flickinger JC, Lunsford LD: Management of brain metastases from ovarian and endometrial carcinoma with stereotactic radiosurgery. Cancer; 2008 Nov 1;113(9):2610-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of brain metastases from ovarian and endometrial carcinoma with stereotactic radiosurgery.
  • BACKGROUND: Metastases to the brain from ovarian and endometrial carcinoma are uncommon and to the authors' knowledge consensus regarding optimal management is lacking.
  • Stereotactic radiosurgery (SRS) has proven useful for the treatment of many benign and malignant brain tumors.
  • METHODS: Twenty-seven patients with brain metastases underwent gamma-knife SRS.
  • Eighteen patients also received whole-brain radiotherapy.
  • A total of 68 tumors were treated with gamma-knife SRS.
  • The median survival was 7 months after the initial diagnosis of brain metastasis and 5 months after SRS.
  • The 1-year survival rate after radiosurgery was 15% and that from the diagnosis of brain metastases was 22%.
  • On final imaging, all tumors were controlled without further growth.
  • CONCLUSIONS: SRS is an acceptable choice for the treatment of brain metastases resulting from ovarian and endometrial carcinoma, and provides local tumor control with limited morbidity.
  • [MeSH-major] Brain Neoplasms / surgery. Cranial Irradiation. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology. Radiosurgery
  • [MeSH-minor] Disease-Free Survival. Female. Follow-Up Studies. Humans. Middle Aged. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18780313.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. De Marinis L, Fusco A, Bianchi A, Aimaretti G, Ambrosio MR, Scaroni C, Cannavo S, Di Somma C, Mantero F, degli Uberti EC, Giordano G, Ghigo E: Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report. J Endocrinol Invest; 2006 Jun;29(6):516-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypopituitarism findings in patients with primary brain tumors 1 year after neurosurgical treatment: preliminary report.
  • It may occur after neurosurgical treatment of brain tumors arising near sella turcica.
  • The aim of this study was to evaluate pituitary function in particular GH deficiency (GHD) in patients submitted to neurosurgery for benign tumors of the central nervous system (CNS) not involving hypothalamic-pituitary region.
  • We observed 37 patients with benign brain tumors [13 males, 24 females, age: 54.6+/-13.9 yr; body mass index (BMI): 25.1+/-4.0 kg/m2] performing a basic evaluation of the pituitary function and a dynamic test of the GH/IGF-I axis [GHRH (1 microg/kg iv)+arginine (0.5 g/kg iv) test] for 3 and 12 months after the neurosurgical treatment.
  • This data suggests that hypopituitarism of various degree may develop in patients who are submitted to neurosurgery for primary brain tumors, even far from hypothalamic-pituitary region.
  • [MeSH-major] Brain Neoplasms / surgery. Hypopituitarism / etiology. Postoperative Complications

  • Genetic Alliance. consumer health - Hypopituitarism.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. ESTRADIOL .
  • Hazardous Substances Data Bank. LEVOTHYROXINE .
  • Hazardous Substances Data Bank. TESTOSTERONE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • Hazardous Substances Data Bank. MENOTROPINS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 1998 Jul 11;352(9122):127-34 [9672293.001]
  • [Cites] Endocrine. 2001 Jun;15(1):29-38 [11572322.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Dec;90(12):6355-60 [16144946.001]
  • [Cites] Clin Endocrinol (Oxf). 2004 Sep;61(3):320-6 [15355447.001]
  • [Cites] J Clin Endocrinol Metab. 1998 May;83(5):1615-8 [9589665.001]
  • [Cites] J Endocrinol Invest. 2004 Dec;27(11):1048-54 [15754737.001]
  • [Cites] Horm Res. 2004;62 Suppl 1:26-33 [15761229.001]
  • [Cites] J Cereb Blood Flow Metab. 1998 Aug;18(8):833-9 [9701344.001]
  • [Cites] Horm Res. 2003;59 Suppl 1:1-11 [12566714.001]
  • [Cites] Neuropathol Appl Neurobiol. 1997 Aug;23(4):307-14 [9292869.001]
  • [Cites] Expert Opin Pharmacother. 2004 May;5(5):1023-31 [15155105.001]
  • [Cites] Neurologist. 2004 May;10(3):113-30 [15140272.001]
  • [Cites] Childs Nerv Syst. 1999 Nov;15(11-12):662-9 [10603007.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S118-24 [15135792.001]
  • [Cites] Neurosurg Clin N Am. 2003 Oct;14(4):571-91 [15024802.001]
  • [Cites] Growth Horm IGF Res. 2004 Jun;14 Suppl A:S114-7 [15135791.001]
  • [Cites] Eur J Pediatr. 1997 Oct;156(10):764-9 [9365064.001]
  • [Cites] Curr Opin Neurol. 2002 Dec;15(6):663-9 [12447103.001]
  • [Cites] Curr Treat Options Oncol. 2004 Dec;5(6):499-509 [15509483.001]
  • [Cites] J Neurosci. 2000 Nov 1;20(21):7994-8004 [11050120.001]
  • [Cites] J Invest Surg. 2004 Sep-Oct;17(5):283-9 [15385261.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Feb;87(2):477-85 [11836272.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):495-506 [12057095.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):377-84 [15015671.001]
  • (PMID = 16840829.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Somatomedins; 3XMK78S47O / Testosterone; 4TI98Z838E / Estradiol; 9002-67-9 / Luteinizing Hormone; 9002-68-0 / Follicle Stimulating Hormone; 9002-71-5 / Thyrotropin; 9002-72-6 / Growth Hormone; 9034-39-3 / Growth Hormone-Releasing Hormone; 94ZLA3W45F / Arginine; Q51BO43MG4 / Thyroxine; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


10. Kumar R, Alavi A: Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma. Curr Opin Oncol; 2005 Mar;17(2):154-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The prognosis is linked directly to the initial stage at the time of diagnosis.
  • Early diagnosis and accurate disease staging is important for appropriate treatment planning.
  • Despite the overall superiority of FDG-PET in the detection of melanoma metastases, it has limitations in detection of early-stage disease (stage I-II), small lung nodules, and brain metastases.
  • False-positive FDG-PET results are due to postsurgical inflammation, other inflammatory lesions, and some benign tumors.
  • [MeSH-major] Fluorodeoxyglucose F18. Melanoma / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals. Skin Neoplasms / radionuclide imaging
  • [MeSH-minor] Humans. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15725921.001).
  • [ISSN] 1040-8746
  • [Journal-full-title] Current opinion in oncology
  • [ISO-abbreviation] Curr Opin Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 37
  •  go-up   go-down


11. Finger PT, Kurli M, Reddy S, Tena LB, Pavlick AC: Whole body PET/CT for initial staging of choroidal melanoma. Br J Ophthalmol; 2005 Oct;89(10):1270-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PET/CT scans were used as a screening tool at the time of their initial diagnosis.
  • Brain involvement was also present in one patient.
  • In seven patients (13.4%) PET/CT imaging detected benign lesions in the bone, lung, lymph nodes, colon, and rectum.
  • [MeSH-major] Choroid Neoplasms / pathology. Melanoma / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Neoplasms / radiography. Bone Neoplasms / radionuclide imaging. Bone Neoplasms / secondary. Female. Fluorodeoxyglucose F18. Humans. Liver Neoplasms / radiography. Liver Neoplasms / radionuclide imaging. Liver Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Positron-Emission Tomography / methods. Radiopharmaceuticals. Spinal Neoplasms / radiography. Spinal Neoplasms / radionuclide imaging. Spinal Neoplasms / secondary. Tomography, X-Ray Computed / methods

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 2001 May;119(5):670-6 [11346394.001]
  • [Cites] Eye (Lond). 1998;12 ( Pt 6):945-8 [10325992.001]
  • [Cites] J Nucl Med. 2003 Nov;44(11):1797-803 [14602862.001]
  • [Cites] JAMA. 2003 Dec 24;290(24):3199-206 [14693872.001]
  • [Cites] J Nucl Med. 2004 Jan;45 Suppl 1:72S-81S [14736838.001]
  • [Cites] J Nucl Med. 2004 Feb;45(2):272-8 [14960647.001]
  • [Cites] J Clin Oncol. 2004 Jun 15;22(12):2438-44 [15197206.001]
  • [Cites] Br J Ophthalmol. 2004 Aug;88(8):1095-7 [15258035.001]
  • [Cites] Surv Ophthalmol. 2004 Sep-Oct;49(5):537-40 [15325198.001]
  • [Cites] Cancer. 1974 Oct;34(4):1001-4 [4424282.001]
  • [Cites] Arch Ophthalmol. 1982 Jun;100(6):939-40 [7092632.001]
  • [Cites] Arch Ophthalmol. 1986 Nov;104(11):1624-5 [3778275.001]
  • [Cites] Ophthalmology. 1991 Mar;98(3):383-9; discussion 390 [2023760.001]
  • [Cites] J Invest Dermatol. 1993 Mar;100(3):326S-331S [8440916.001]
  • [Cites] Arch Ophthalmol. 1996 Jan;114(1):107-8 [8540843.001]
  • [Cites] J Clin Oncol. 1997 Jul;15(7):2589-95 [9215829.001]
  • [Cites] J Exp Clin Cancer Res. 1997 Jun;16(2):201-8 [9261748.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1151-9 [10091801.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2500-7 [12815135.001]
  • (PMID = 16170114.001).
  • [ISSN] 0007-1161
  • [Journal-full-title] The British journal of ophthalmology
  • [ISO-abbreviation] Br J Ophthalmol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ PMC1772897
  •  go-up   go-down


12. Hohenstein C, Herdtle S: Unexpected death from a colloid cyst. Int J Emerg Med; 2010;3(1):65-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Colloid cysts are usually benign brain tumors, which rarely cause acute neurological deterioration with sudden death due to an acute increase of intracranial pressure.
  • CONCLUSION: Subtle distinctions between symptoms due to intracranial hypertension, which typically cause headache and vomiting, and true gastroenteritis are discussed as well as the pathophysiology of neurogenic pulmonary edema and the origin of cerebral-triggered cardiac dysrhythmias.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 1996 Feb;38(2):392-5 [8869070.001]
  • [Cites] Ann Emerg Med. 1997 Apr;29(4):524-8 [9095015.001]
  • [Cites] Clin Neurol Neurosurg. 2002 Sep;104(4):367-70 [12140107.001]
  • [Cites] Childs Nerv Syst. 2006 Mar;22(3):305-9 [16180045.001]
  • [Cites] J Clin Neurosci. 1995 Oct;2(4):307-11 [18638833.001]
  • [Cites] Acta Anaesthesiol Scand. 2007 Apr;51(4):447-55 [17378783.001]
  • [Cites] Physiol Res. 2008;57(4):499-506 [18052674.001]
  • [Cites] Am J Forensic Med Pathol. 2008 Jun;29(2):170-2 [18520488.001]
  • [Cites] Pediatr Cardiol. 2006 Mar-Apr;27(2):286-8 [16463127.001]
  • (PMID = 20414387.001).
  • [ISSN] 1865-1380
  • [Journal-full-title] International journal of emergency medicine
  • [ISO-abbreviation] Int J Emerg Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2850975
  • [Keywords] NOTNLM ; Cardiopulmonary complication / Colloid cyst / Unexpected death
  •  go-up   go-down


13. Gokce M: Analysis of isolated cranial nerve manifestations in patients with cancer. J Clin Neurosci; 2005 Nov;12(8):882-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In a prospective study over a 16 month period, 20 of 242 patients presented with isolated CN manifestations, and were assessed for the following: primary site; CN symptoms and signs; length of time between primary diagnosis and neurological involvement; and survival following the neurological diagnosis.
  • They included meningeal carcinomatosis (10/16), brain stem metastases (3/16), primary brain astrocytomas (1/16), and metastases out of the central nervous system (2/16).
  • Although most of the isolated CN manifestations were due to systemic metastasis, in particular to the meninges, up to 20% were related to benign conditions.
  • [MeSH-major] Cranial Nerve Diseases / etiology. Neoplasms / complications
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Humans. Magnetic Resonance Imaging. Male. Meningeal Neoplasms / secondary. Middle Aged. Neoplasm Metastasis / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16326269.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


14. Kubo O, Chernov M, Izawa M, Hayashi M, Muragaki Y, Maruyama T, Hori T, Takakura K: Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation? Minim Invasive Neurosurg; 2005 Dec;48(6):334-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant progression of benign brain tumors after gamma knife radiosurgery: is it really caused by irradiation?
  • Malignant transformation of benign neoplasm after radiosurgery is usually diagnosed based on the initial presence of benign tumor, its exposure to ionizing radiation, elapsed time from radiation exposure to malignant progression, and different histological characteristics or growth rate of the regrowing tumor comparing with those originally treated.
  • Three presented cases fulfilled these diagnostic criteria; however, it seems that progression of the tumors (schwannoma, meningioma, chordoma) resulted from the natural course of the disease, rather than represented side effects of gamma knife radiosurgery.
  • Evaluation of the proliferative potential of the benign neoplasm before radiosurgical treatment either directly, if tumor sampling is available, or indirectly, by calculation of the tumor growth rate and/or analysis of the data of the metabolic imaging (PET, MRS) is important for identification of "aggressive" subtypes, precise prediction of prognosis, and confirmation of the radiation-induced malignant transformation in cases of tumor regrowth.
  • [MeSH-major] Brain Neoplasms / surgery. Cell Transformation, Neoplastic / radiation effects. Chordoma / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neoplasms, Radiation-Induced / physiopathology. Neurilemmoma / surgery. Radiosurgery / adverse effects
  • [MeSH-minor] Adult. Brain Diseases / surgery. Cell Proliferation. Female. Humans. Male. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16432782.001).
  • [ISSN] 0946-7211
  • [Journal-full-title] Minimally invasive neurosurgery : MIN
  • [ISO-abbreviation] Minim Invasive Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


15. Simis A, Pires de Aguiar PH, Leite CC, Santana PA Jr, Rosemberg S, Teixeira MJ: Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence. Surg Neurol; 2008 Nov;70(5):471-7; discussion 477
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritumoral brain edema in benign meningiomas: correlation with clinical, radiologic, and surgical factors and possible role on recurrence.
  • METHODS: Sixty-one patients with benign meningiomas were chosen for surgical treatment by the Group of Brain Tumors and Metastasis of the Department of Neurosurgery.
  • Tumors located in the cavernous sinus, tuberculum sellae, foramen magnum, ventricles, and petroclival region were excluded.
  • CONCLUSION: Peritumoral brain edema may be related to the invading potential of meningiomas and may play a role in the recurrence potential of the tumor.
  • [MeSH-major] Brain Edema / complications. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Neoplasm Recurrence, Local / etiology

  • Genetic Alliance. consumer health - Edema.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586307.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Strojnik T, Kavalar R, Zajc I, Diamandis EP, Oikonomopoulou K, Lah TT: Prognostic impact of CD68 and kallikrein 6 in human glioma. Anticancer Res; 2009 Aug;29(8):3269-79
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIMS: To evaluate the expression of CD68 and kallikrein 6 in human gliomas, and investigate their prognostic significance for survival of brain cancer patients in comparison to some known prognostic markers.
  • PATIENTS AND METHODS: Histological sections of 51 primary astrocytic tumours (11 benign, 40 malignant) were immunohistochemically stained for CD68, cathepsin B, kallikrein 6 and Ki-67.
  • CD68 and kallikrein 6 expressions were also analyzed by real-time PCR in nine brain tumour biopsies.
  • RESULTS: Both microglia and tumour cells expressed CD68.
  • High CD68 and cathepsin B staining scores were significantly, more frequent in the malignant than in the benign tumours (p=0.036 and p=0.014, respectively).
  • In contrast, the benign group presented a stronger immunoreactivity for kallikrein 6 compared with the malignant tumours (p=0.013).
  • A CD68 staining score of tumour cells higher than 3 was a significant predictor of shorter overall survival (p<0.01) in all patients and of borderline significance in the malignant group (p=0.057).
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Differentiation, Myelomonocytic / metabolism. Brain Neoplasms / metabolism. Glioma / metabolism. Kallikreins / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19661345.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation, Myelomonocytic; 0 / CD68 antigen, human; 0 / RNA, Messenger; EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


17. Jinhu Y, Jianping D, Jun M, Hui S, Yepeng F: Metastasis of a histologically benign choroid plexus papilloma: case report and review of the literature. J Neurooncol; 2007 May;83(1):47-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of a histologically benign choroid plexus papilloma: case report and review of the literature.
  • Cerebrospinal metastases of benign choroid plexus papillomas (CPPs) are extremely rare.
  • Plain CT scan of the cranium revealed a partly calcified tumor filling the fourth ventricle and its right recess.
  • Cranial MRI showed an inhomogeneously contrast-enhancing tumor and leptomeningeal enhancement encasing the brain stem.
  • Complete resection of the tumor was carried out, and seedings to the floor of the fourth ventricle and cervico-medullary junction were found during the operation.
  • While intraoperative frozen section suggested pathology of papillary ependymoma or CPP, to our surprise, final histological examination revealed a benign choroid plexus papilloma.
  • Two months after the first operation, on follow-up MRI of the cranium, the leptomeningeal enhancement encasing the brain stem had resolved spontaneously.
  • This special case helps increase our understanding of benign CPPs and expands our differential diagnostic consideration of lesions with similar manifestations.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Cerebral Ventricle Neoplasms / secondary. Choroid Plexus Neoplasms / pathology. Choroid Plexus Neoplasms / secondary. Fourth Ventricle. Papilloma / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. Magnetic Resonance Imaging. Neoplasm Seeding. Neurosurgical Procedures / adverse effects. Subarachnoid Space. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Choroid Plexus Papilloma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1970 Nov;110(3):608-17 [5489698.001]
  • [Cites] Surg Neurol. 1999 Jun;51(6):621-9 [10369230.001]
  • [Cites] Am J Obstet Gynecol. 2000 Oct;183(4):956-63 [11035346.001]
  • [Cites] Clin Neurol Neurosurg. 1998 Sep;100(3):165-86 [9822838.001]
  • [Cites] J Neurosurg. 1998 Apr;88(4):757-60 [9525724.001]
  • [Cites] J Neurooncol. 2004 May;68(1):49-55 [15174521.001]
  • [Cites] Surg Neurol. 1991 Jul;36(1):54-8 [2053075.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 Jan;33(1):32-5 [7680781.001]
  • [Cites] Neurochirurgie. 1986;32(3):258-61 [3762840.001]
  • [Cites] Neurosurg Focus. 2006 Jan 15;20(1):E10 [16459990.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(7):802-10 [8869707.001]
  • [Cites] Arch Pathol Lab Med. 1977 Jul;101(7):366-8 [577391.001]
  • [Cites] Neuroradiology. 2000 Sep;42(9):657-61 [11071438.001]
  • [Cites] Pediatr Neurosci. 1985-1986;12(4-5):196-201 [3843618.001]
  • [Cites] Noshuyo Byori. 1996 Nov;13(2):99-105 [8958514.001]
  • [Cites] Br J Radiol. 1992 Sep;65(777):754-7 [1393408.001]
  • [Cites] Neurology. 2005 Sep 27;65(6):842 [16186520.001]
  • [Cites] J Neurosurg. 1960 Nov;17:1002-27 [13768200.001]
  • [Cites] Clin Imaging. 1996 Apr-Jun;20(2):85-90 [8744814.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 May-Jun;12(3):564-5 [2058519.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 May-Jun;8(3):469-72 [3111207.001]
  • [Cites] Surg Neurol. 1982 Nov;18(5):367-71 [6983728.001]
  • [Cites] Acta Neurochir (Wien). 2002 Jul;144(7):723-8 [12181706.001]
  • [Cites] Neurology. 1995 Oct;45(10):1801-7 [7477972.001]
  • [Cites] Neurosurg Rev. 1981;4(3):129-37 [7301142.001]
  • [Cites] Aust N Z J Med. 1997 Oct;27(5):597-8 [9404596.001]
  • [Cites] Folia Neuropathol. 2001;39(3):209-13 [11770132.001]
  • [Cites] Surg Neurol. 1987 May;27(5):466-8 [3563861.001]
  • [Cites] J Neurooncol. 1992 Jan;12 (1):69-74 [1541980.001]
  • [Cites] J Neurosurg. 1998 Mar;88(3):521-8 [9488307.001]
  • [Cites] AJNR Am J Neuroradiol. 1994 Apr;15(4):633-8 [8010262.001]
  • (PMID = 17387433.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


18. Al-Khalaf HH, Lach B, Allam A, Hassounah M, Alkhani A, Elkum N, Alrokayan SA, Aboussekhra A: Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells. Brain Res; 2008 Jan 10;1188:25-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although meningiomas represent the most common class of tumors of the central nervous system, the molecular events underlying their genesis and development are still not well defined, and therapeutic approaches based on the genetics of these tumors are currently lacking.
  • In addition, we present evidence that the level of the anti-apoptosis survivin protein is high in these benign tumors.
  • [MeSH-major] Apoptosis / physiology. Cyclin-Dependent Kinase 6 / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cisplatin / pharmacology. Female. Flow Cytometry. Humans. Hydroxyurea / pharmacology. Immunoblotting. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / drug effects. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-bcl-2 / radiation effects. Radiotherapy. Signal Transduction / drug effects. Signal Transduction / physiology. Up-Regulation / drug effects. Up-Regulation / physiology. Up-Regulation / radiation effects. bcl-2-Associated X Protein / drug effects. bcl-2-Associated X Protein / metabolism. bcl-2-Associated X Protein / radiation effects

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18048012.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Retinoblastoma Protein; 0 / bcl-2-Associated X Protein; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6; Q20Q21Q62J / Cisplatin; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


19. Bougrine F, Bacha D, Chouchane O, Laabidi B, Yeades M, Bouziani A: [Intracerebral schwannoma: case report]. Neurochirurgie; 2007 Nov;53(5):387-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was removed through a right parietal craniotomy.
  • The most popular hypothesis argues that these tumors arise from the proliferation of Schwann cells in the perivascular nerve plexii.
  • CONCLUSIONS: Intracerebral schwannoma is an extremely rare benign tumor.
  • The importance of recognizing this tumor is stressed, particularly in younger patients, given its benign nature, radiological resemblance to other tumors and favorable response to resection without toxic treatment.
  • [MeSH-major] Brain Neoplasms / pathology. Neurilemmoma / pathology
  • [MeSH-minor] Adult. Female. Humans. Immunohistochemistry. Intracranial Hypertension / etiology. Magnetic Resonance Imaging. Neoplasm Metastasis. Neurosurgical Procedures. Seizures / etiology

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17884108.001).
  • [ISSN] 0028-3770
  • [Journal-full-title] Neuro-Chirurgie
  • [ISO-abbreviation] Neurochirurgie
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


20. Yang Y, Shao N, Luo G, Li L, Nilsson-Ehle P, Xu N: Relationship between PTEN gene expression and differentiation of human glioma. Scand J Clin Lab Invest; 2006;66(6):469-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor-adjacent normal tissues and benign brain tumors were used as controls.
  • RESULTS: PTEN mRNA levels were significantly lower in the glioma tissues than in the benign brain tumors and tumor-adjacent normal tissues, whereas there were no statistical differences between benign brain tumor and the tumor-adjacent normal tissues.
  • [MeSH-major] Brain Neoplasms / genetics. Brain Neoplasms / pathology. Glioma / genetics. Glioma / pathology. PTEN Phosphohydrolase / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / genetics. Astrocytoma / pathology. Child. Female. Gene Expression. Genes, Tumor Suppressor. Glioblastoma / genetics. Glioblastoma / pathology. Glyceraldehyde-3-Phosphate Dehydrogenases / genetics. Humans. Male. Meningioma / genetics. Meningioma / pathology. Middle Aged. Mutation. Neuroma, Acoustic / genetics. Neuroma, Acoustic / pathology. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Neoplasm / genetics. RNA, Neoplasm / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000554.001).
  • [ISSN] 0036-5513
  • [Journal-full-title] Scandinavian journal of clinical and laboratory investigation
  • [ISO-abbreviation] Scand. J. Clin. Lab. Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 1.2.1.- / Glyceraldehyde-3-Phosphate Dehydrogenases; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


21. Rowe J, Grainger A, Walton L, Silcocks P, Radatz M, Kemeny A: Risk of malignancy after gamma knife stereotactic radiosurgery. Neurosurgery; 2007 Jan;60(1):60-5; discussion 65-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the risk of radiosurgery to cause malignant transformation in benign tumors or to induce new malignancies.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / mortality. Neoplasm Seeding. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17228253.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Schmidt GP, Baur-Melnyk A, Herzog P, Schmid R, Tiling R, Schmidt M, Reiser MF, Schoenberg SO: High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system. Invest Radiol; 2005 Dec;40(12):743-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system.
  • OBJECTIVE: The objective of this study was to compare the accuracy in staging of various malignant tumors with whole-body magnetic resonance imaging (WB-MRI) using parallel imaging (PAT) and positron emission tomography-computed tomography (PET-CT).
  • MATERIALS AND METHODS: In a prospective study, 41 patients withoncologic diseases underwent [F]-fluoro-2-deoxy-D-glucose PET-CT for tumor staging and WB-MRI on a 32-channel-scanner with the use of PAT.
  • Coronal T1w and STIR sequences at 5 body levels, axial HASTE imaging of the lung, and contrast-enhanced T1w sequences of the liver, brain, and abdomen were performed.
  • RESULTS: Three primary and 4 recurrent tumors were detected; one recurrent tumor was missed with WB-MRI.
  • Sixty benign and 60 malignant lymph nodes were detected with a sensitivity of 98% and specificity of 83% for PET-CT and 80%/75% for WB-MRI, respectively.
  • One hundred ninety-one malignant and 77 benign distant lesions were detected with a sensitivity/specificity of 82% for PET-CT and 96%/82% for WB-MRI.
  • CONCLUSION: WB-MRI and PET-CT are reliable imaging modalities for tumor staging.
  • [MeSH-major] Magnetic Resonance Imaging / methods. Neoplasms / diagnosis. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods. Whole Body Imaging / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Image Enhancement / methods. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Reproducibility of Results. Sensitivity and Specificity. Subtraction Technique

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16304476.001).
  • [ISSN] 0020-9996
  • [Journal-full-title] Investigative radiology
  • [ISO-abbreviation] Invest Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Jesneck JL, Mukherjee S, Yurkovetsky Z, Clyde M, Marks JR, Lokshin AE, Lo JY: Do serum biomarkers really measure breast cancer? BMC Cancer; 2009 May 28;9:164
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The classifiers distinguished normal tissue from benign lesions similarly at AUC = 0.80 +/- 0.05.
  • However, the serum proteins of benign and malignant lesions were indistinguishable (AUC = 0.55 +/- 0.06).
  • The classification tasks of normal vs. cancer and normal vs. benign selected the same top feature: MIF, which suggests that the biomarkers indicated inflammatory response rather than cancer.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biomark. 2006;2(6):235-48 [17264395.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2007 Feb;16(2):334-41 [17301268.001]
  • [Cites] Ann Surg Oncol. 2007 Sep;14(9):2470-6 [17594124.001]
  • [Cites] Med Decis Making. 2000 Jul-Sep;20(3):323-31 [10929855.001]
  • [Cites] Med Phys. 2000 Jul;27(7):1509-22 [10947254.001]
  • [Cites] Semin Oncol. 2001 Feb;28(1):53-67 [11254867.001]
  • [Cites] Proteomics. 2001 Oct;1(10):1205-15 [11721633.001]
  • [Cites] Science. 2002 Jun 28;296(5577):2391-4 [12089442.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1194-7 [12142372.001]
  • [Cites] Clin Chem. 2002 Aug;48(8):1296-304 [12142387.001]
  • [Cites] Cancer Res. 2002 Nov 15;62(22):6740-9 [12438275.001]
  • [Cites] Expert Opin Ther Targets. 2003 Apr;7(2):153-64 [12667094.001]
  • [Cites] Proteomics. 2003 Apr;3(4):433-9 [12687611.001]
  • [Cites] J Neurochem. 2003 Jul;86(2):519-28 [12871593.001]
  • [Cites] Bioinformatics. 2003 Aug 12;19(12):1484-91 [12912828.001]
  • [Cites] Thyroid. 2003 Jun;13(6):547-51 [12930598.001]
  • [Cites] Radiology. 2003 Oct;229(1):3-8 [14519861.001]
  • [Cites] Med Phys. 2004 Jan;31(1):81-90 [14761024.001]
  • [Cites] Clin Chem. 2004 Mar;50(3):559-63 [14726467.001]
  • [Cites] Cancer. 2004 Oct 15;101(8):1767-75 [15386335.001]
  • [Cites] Anticancer Res. 2004 Sep-Oct;24(5B):3221-4 [15510614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1976 Dec;73(12):4329-33 [188033.001]
  • [Cites] Radiology. 1984 Feb;150(2):335-7 [6691085.001]
  • [Cites] Radiology. 1987 Jan;162(1 Pt 1):167-70 [3024209.001]
  • [Cites] Invest Radiol. 1988 Oct;23(10):729-33 [3056868.001]
  • [Cites] Blood. 1989 May 1;73(6):1504-12 [2653458.001]
  • [Cites] Breast Cancer Res Treat. 1989 Mar;13(2):123-33 [2730960.001]
  • [Cites] Cancer. 1990 Jan 15;65(2):193-9 [2295042.001]
  • [Cites] Endocrinol Jpn. 1989 Dec;36(6):873-9 [2483831.001]
  • [Cites] Immunol Today. 1993 Oct;14(10):506-12 [7506035.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Mar;80(3):922-6 [7883851.001]
  • [Cites] J Clin Invest. 1995 Mar;95(3):1370-6 [7883984.001]
  • [Cites] J Exp Med. 1996 Jan 1;183(1):147-57 [8551218.001]
  • [Cites] Am J Prev Med. 1996 Sep-Oct;12(5):340-1 [8909643.001]
  • [Cites] FASEB J. 1996 Dec;10(14):1607-13 [9002552.001]
  • [Cites] Clin Biochem. 1997 Feb;30(1):53-6 [9056110.001]
  • [Cites] Infect Immun. 1997 Nov;65(11):4734-7 [9353058.001]
  • [Cites] Cell. 1998 May 1;93(3):411-22 [9590175.001]
  • [Cites] Biochimie. 1998 Aug-Sep;80(8-9):673-87 [9865490.001]
  • [Cites] J Urol. 1999 Aug;162(2):293-306 [10411025.001]
  • [Cites] Science. 1999 Jul 30;285(5428):727-9 [10426993.001]
  • [Cites] Oncology. 2004;67(5-6):359-67 [15713991.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):529-34 [15863156.001]
  • [Cites] J Thromb Haemost. 2008 Sep;6(9):1586-94 [18541003.001]
  • [Cites] Cancer Control. 2007 Oct;14(4):360-8 [17914336.001]
  • [Cites] Pathol Oncol Res. 2007;13(4):360-4 [18158573.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1508-17 [18257519.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1419-26 [18303830.001]
  • [Cites] J Proteome Res. 2008 Apr;7(4):1395-402 [18303834.001]
  • [Cites] Cancer Biomark. 2008;4(2):73-81 [18503158.001]
  • [Cites] Am J Obstet Gynecol. 2008 Sep;199(3):215-23 [18468571.001]
  • [Cites] J Proteome Res. 2009 Jan;8(1):362-73 [19053527.001]
  • [Cites] Cancer Treat Rev. 2000 Apr;26(2):91-102 [10772967.001]
  • [Cites] Bioinformatics. 2005 May 15;21(10):2394-402 [15713736.001]
  • [Cites] Intern Med J. 2005 Jul;35(7):419-26 [15958113.001]
  • [Cites] Tumour Biol. 2005 Nov-Dec;26(6):281-93 [16254457.001]
  • [Cites] Clin Chem. 2006 Mar;52(3):345-51 [16410341.001]
  • [Cites] Breast Cancer Res Treat. 2006 Mar;96(1):83-90 [16322896.001]
  • [Cites] Hell J Nucl Med. 2006 Jan-Apr;9(1):60-4 [16617400.001]
  • [Cites] BMC Bioinformatics. 2006;7:197 [16606446.001]
  • [Cites] IEEE Trans Med Imaging. 2006 May;25(5):571-81 [16689261.001]
  • [Cites] Br J Haematol. 2006 Jun;133(6):692-4 [16704450.001]
  • [Cites] Brain. 2006 Nov;129(Pt 11):3042-50 [17071923.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19472-7 [17159154.001]
  • [Cites] N Engl J Med. 2006 Dec 21;355(25):2631-9 [17182988.001]
  • [Cites] Proteomics. 2007 Jan;7(2):299-312 [17205601.001]
  • (PMID = 19476629.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 84955; United States / NCI NIH HHS / CA / R01 CA-112437-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2696469
  •  go-up   go-down


24. Shimizu J, Matsumoto M, Yamazaki E, Yasue M: Spontaneous regression of an asymptomatic meningioma associated with discontinuation of progesterone agonist administration. Neurol Med Chir (Tokyo); 2008 May;48(5):227-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain computed tomography incidentally revealed a left frontal lobe tumor measuring 5 cm in a diameter.
  • The patient had a history of taking chlormadinone acetate (a progesterone agonist) prescribed several years previously as treatment for benign prostatic hypertrophy.
  • The tumor was seen as an isointense lesion on T(1)-weighted magnetic resonance (MR) images with enhancement by gadolinium, and as a heterogeneously hyperintense mass on T(2)-weighted MR images.
  • The tentative diagnosis was left frontal meningioma attached to the sphenoid ridge or sphenoid plane.
  • The medication for benign prostatic hypertrophy was changed from chlormadinone acetate to naftopidil (an alpha-2-blocker) about 9 months after his first presentation.
  • Computed tomography and MR imaging performed at this time revealed remarkable regression of the tumor.
  • The signal intensity change with regression of the tumor on T(2)-weighted images was observed as a hypointense lesion.
  • [MeSH-major] Androgen Antagonists / administration & dosage. Chlormadinone Acetate / administration & dosage. Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Regression, Spontaneous

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. CHLORMADINONE ACETATE .
  • Hazardous Substances Data Bank. PROGESTERONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18497498.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0SY050L61N / Chlormadinone Acetate; 4G7DS2Q64Y / Progesterone
  •  go-up   go-down


25. Boviatsis EJ, Bouras TI, Kouyialis AT, Themistocleous MS, Sakas DE: Impact of age on complications and outcome in meningioma surgery. Surg Neurol; 2007 Oct;68(4):407-11; discussion 411
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Surgery for benign brain tumors in elderly patients without severe general health problems is an acceptable practice, as results are comparable with the ones of younger patients.
  • Tumor removal rate was not significantly different in the 2 groups.
  • Regarding each complication, postoperative hematoma, infections, and deep vein thrombosis were more frequent in elderly patients, presenting various degrees of statistical significance, whereas postoperative brain edema, hydrocephalus, and cardiorespiratory incidents presented no statistically significant difference.
  • [MeSH-major] Meningioma / surgery. Postoperative Complications / epidemiology. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adult. Age Factors. Aged. Aged, 80 and over. Cerebral Hemorrhage / etiology. Craniotomy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Nervous System Diseases / epidemiology. Neurosurgical Procedures. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17586023.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Sheedy SP, Welker KM, DeLone DR, Gilbertson JR: CNS metastases of carcinoma ex pleomorphic adenoma of the parotid gland. AJNR Am J Neuroradiol; 2006 Aug;27(7):1483-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic adenomas (PAs), also known as benign mixed tumors, are common tumors of the parotid gland.
  • These tumors occasionally undergo malignant transformation, with potentially devastating consequences.
  • This case report presents the clinical and radiographic features of a rare case of biopsy proved brain and spinal cord metastases arising from carcinoma ex PA of the parotid gland.
  • [MeSH-major] Adenocarcinoma / secondary. Adenoma, Pleomorphic / pathology. Brain Neoplasms / secondary. Neoplasms, Multiple Primary / pathology. Parotid Neoplasms / pathology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Adult. Fatal Outcome. Humans. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908563.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Huang CF, Chiou SY, Wu MF, Tu HT, Liu WS, Chuang JC: Apparent diffusion coefficients for evaluation of the response of brain tumors treated by Gamma Knife surgery. J Neurosurg; 2010 Dec;113 Suppl:97-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apparent diffusion coefficients for evaluation of the response of brain tumors treated by Gamma Knife surgery.
  • The authors hypothesized that loss of tumor cells after Gamma Knife surgery (GKS) may alter the ADC value and used diffusion weighted MR imaging (DW imaging) to evaluate cellular changes in brain tumors to detect their treatment response and the efficacy of GKS.
  • METHODS: In this paper the authors describe a prospective trial involving 86 patients harboring 38 solid or predominantly solid brain metastases, 30 meningiomas, and 24 acoustic neuromas that were treated by GKS.
  • Follow-up MR images and clinical outcomes were reviewed at 3-month intervals for metastatic lesions and at 6-month intervals for benign tumors.
  • Calcification (p = 0.006) and tumor recurrence (p = 0.025) significantly prevented a rise in the ADC level.The mean ADC value for all solid acoustic neuromas was 1.06 ± 0.17 × 10-3 mm2/sec before GKS.
  • At the last mean MR imaging follow-up there appeared to be tumor enlargement in 3 patients (12.5%); however, since the ADC values in these patients were significantly higher than the preradiosurgery values, the finding was considered to be a sign of radiation necrosis rather than tumor recurrence.
  • The mean ADC value of metastatic tumors was 1.05 ± 0.12 × 10-3 mm2/sec before GKS.
  • Magnetic resonance imaging showed that 89% of these tumors had been controlled by GKS.
  • In some patients in whom imaging findings are equivocal, ADC values may also be used to distinguish radiation-induced necrosis from tumor recurrence.(DOI: 10.3171/2010.7.GKS10864)
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Diffusion Magnetic Resonance Imaging / methods. Image Processing, Computer-Assisted / methods. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Echo-Planar Imaging. Female. Humans. Male. Meningioma / pathology. Meningioma / surgery. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neuroma, Acoustic / pathology. Neuroma, Acoustic / surgery. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21222290.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Yu R, Melmed S: Pathogenesis of pituitary tumors. Prog Brain Res; 2010;182:207-27
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathogenesis of pituitary tumors.
  • Pituitary tumors are common and mostly benign neoplasia which cause excess or deficiency of pituitary hormones and compressive damage to adjacent organs.
  • PTTG (pituitary tumor-transforming gene) and HMGA2], tumor suppressor gene inactivation (e.g.
  • MEN1 and PRKAR1A), epigenetic changes (e.g. methylation) and humoral factors (e.g. ectopic production of stimulating hormones) are all possible pituitary tumor initiators; the micro-environment of pituitary tumors including steroid milieu, angiogenesis and abnormal cell adhesion further promote tumor growth.
  • Senescence, a cellular defence mechanism against malignant transformation, may explain the benign nature of at least some pituitary tumors.
  • We suggest that future research on pituitary tumor pathogenesis should incorporate systems approaches, and address regulatory mechanisms for pituitary cell proliferation, development of new animal models of pituitary tumor and isolation of functional human pituitary tumor cell lines.
  • [MeSH-major] Pituitary Neoplasms / genetics. Pituitary Neoplasms / pathology
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. HMGA2 Protein / genetics. HMGA2 Protein / metabolism. Humans. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Securin

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20541667.001).
  • [ISSN] 1875-7855
  • [Journal-full-title] Progress in brain research
  • [ISO-abbreviation] Prog. Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / HMGA2 Protein; 0 / Neoplasm Proteins; 0 / Securin; 0 / pituitary tumor-transforming protein 1, human
  •  go-up   go-down


29. Scoles DR: The merlin interacting proteins reveal multiple targets for NF2 therapy. Biochim Biophys Acta; 2008 Jan;1785(1):32-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The neurofibromatosis 2 (NF2) tumor suppressor protein merlin is commonly mutated in human benign brain tumors.
  • Review of all of the merlin interacting proteins and functional consequences of losses of these interactions reveals multiple merlin actions in PI3-kinase, MAP kinase and small GTPase signaling pathways that might be targeted to inhibit the proliferation of NF2 tumors.
  • [MeSH-minor] Animals. Binding Sites. Cytoskeletal Proteins / metabolism. Humans. Models, Biological. Protein Folding. Tumor Suppressor Proteins / administration & dosage. Tumor Suppressor Proteins / metabolism


30. Juric-Sekhar G, Zarkovic K, Waeg G, Cipak A, Zarkovic N: Distribution of 4-hydroxynonenal-protein conjugates as a marker of lipid peroxidation and parameter of malignancy in astrocytic and ependymal tumors of the brain. Tumori; 2009 Nov-Dec;95(6):762-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of 4-hydroxynonenal-protein conjugates as a marker of lipid peroxidation and parameter of malignancy in astrocytic and ependymal tumors of the brain.
  • It results in the production of 4-hydroxynonenal (HNE), which plays a crucial role in hypoxic brain injury, neuronal degeneration and apoptosis.
  • The aim of this study was to evaluate the expression of HNE in 120 astrocytic and 40 ependymal tumors in relation to tumor type, grade of malignancy, angiogenesis, and presence of necrosis and apoptosis.
  • RESULTS: HNE-protein adducts were found in all tumors.
  • The incidence of HNE-immunopositive tumor cells increased with increasing grades of malignancy.
  • Significantly higher HNE expression was found in tumor cells of glioblastomas multiforme than in cells of pilocytic astrocytomas (P < 0.005), and in anaplastic ependymomas than in benign ependymomas (P < 0.01).
  • HNE-immunopositive tumor cells were distributed more diffusely than in perivascular locations (P < 0.05).
  • HNE was expressed in the endothelium of almost all tumor vessels, but its expression in the walls of the vessels was significantly higher in diffuse and anaplastic astrocytomas than in pilocytic astrocytomas and glioblastomas multiforme (P < 0.05).
  • The number of microvessels containing HNE in their endothelium and walls was significantly associated with the grade of malignancy in both astrocytic (P < 0.001) and ependymal tumors (P < 0.05), although microvessels in pilocytic astrocytomas were significantly more numerous (P < 0.05) than in diffuse astrocytomas.
  • CONCLUSIONS: LPO seems to be a common pathological process in astrocytic and ependymal glial tumors, proportional to the level of malignancy and neovascularization.
  • Therefore, HNE might be involved in the damage of brain cells and the induction of malignancy.
  • [MeSH-major] Aldehydes / analysis. Astrocytoma / chemistry. Biomarkers, Tumor / analysis. Brain Neoplasms / chemistry. Brain Neoplasms / pathology. Ependymoma / chemistry. Lipid Peroxidation. Neoplasm Proteins / analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20210242.001).
  • [ISSN] 0300-8916
  • [Journal-full-title] Tumori
  • [ISO-abbreviation] Tumori
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Biomarkers, Tumor; 0 / Cross-Linking Reagents; 0 / Neoplasm Proteins; K1CVM13F96 / 4-hydroxy-2-nonenal
  •  go-up   go-down


31. Gabeau-Lacet D, Grant E, Stemmer-Rachamimov A, Yock T, Tarbell NJ: Sellar abnormalities in female first-degree relatives. Clin Neurol Neurosurg; 2008 Feb;110(2):202-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each of these cases was diagnosed and managed differently, illustrating the relative importance of radiographic imaging, tumor markers and histopathologic examination in the diagnosis and treatment of intracranial disease.
  • One daughter was treated presumptively for germinoma based on characteristic radiographic studies and slightly elevated tumor marker.
  • The other daughter's lesion exhibited radiographic characteristics concerning for pituitary macroadenoma but with slightly elevated germ cell tumor marker, raising the suspicion for germinoma.
  • Biopsy of the intrasellar mass revealed only proteinaceous material and normal anterior pituitary, consistent with cyst content without evidence of neoplasm.
  • Without a clear unifying diagnosis it is difficult to posit an underlying pathology or genetic mechanisms in this unusual set of cases.
  • At least two of the patients had benign cysts.
  • The diagnosis of the third patient is unclear as there was no tissue biopsy.
  • However, it is highly improbable that three female first-degree relatives would develop such lesions in the same brain region simply by chance.
  • [MeSH-major] Central Nervous System Cysts / genetics. Central Nervous System Cysts / pathology. Pituitary Neoplasms / genetics. Pituitary Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035480.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


32. Kaynar MY, Sanus GZ, Hnimoglu H, Kacira T, Kemerdere R, Atukeren P, Gumustas K, Canbaz B, Tanriverdi T: Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma. J Clin Neurosci; 2008 Sep;15(9):1036-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma.
  • There was no statistically significant difference between the two types of tumor (p=0.264).
  • These findings indicate that HIF-1alpha is elevated in both TM and GBM, suggesting that although hypoxia is one of the most important and powerful stimuli for HIF-1alpha elevation and consequently angiogenesis, other mechanisms may play roles in HIF-1alpha stimulation in benign brain tumors such as TM.
  • [MeSH-major] Brain Neoplasms / metabolism. Glioblastoma / metabolism. Hypoxia-Inducible Factor 1, alpha Subunit / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Anoxia / diagnosis. Anoxia / metabolism. Anoxia / physiopathology. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cell Hypoxia / physiology. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neovascularization, Pathologic / etiology. Neovascularization, Pathologic / metabolism. Neovascularization, Pathologic / physiopathology. Predictive Value of Tests. Up-Regulation / physiology

  • Genetic Alliance. consumer health - Glioblastoma.
  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18621534.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / HIF1A protein, human; 0 / Hypoxia-Inducible Factor 1, alpha Subunit
  •  go-up   go-down


33. Yao Y, Tang X, Li S, Mao Y, Zhou L: Brain tumor stem cells: view from cell proliferation. Surg Neurol; 2009 Mar;71(3):274-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain tumor stem cells: view from cell proliferation.
  • A small population of TSCs, which form neurospheres and possess the capacity for self-renewal, has been recently identified in adult and pediatric brain tumors.
  • They differentiate into phenotypically diverse populations, including neuronal, astrocytic, and oligodendroglial cells in vitro and recapitulate original tumors in vivo.
  • The understanding of brain TSCs has been greatly advanced by the knowledge of cell proliferation, which contributes to initiate and sustain the malignant phenotype.
  • In this article, the authors summarized the evidence of the presence of TSCs in human brain tumors and emphasized the significance of the proliferative status of TSCs.
  • Finally, the preliminary evidence that TSCs in malignant brain tumors have more proliferative capacity than stem/progenitor cells in benign brain tumors was discussed.
  • [MeSH-major] Adult Stem Cells / pathology. Brain Neoplasms / pathology. Neoplastic Stem Cells / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249579.001).
  • [ISSN] 0090-3019
  • [Journal-full-title] Surgical neurology
  • [ISO-abbreviation] Surg Neurol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 40
  •  go-up   go-down


34. Ali Y, Rahme R, Moussa R, Abadjian G, Menassa-Moussa L, Samaha E: Multifocal meningeal melanocytoma: a new pathological entity or the result of leptomeningeal seeding? J Neurosurg; 2009 Sep;111(3):488-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningeal melanocytoma is a rare benign CNS tumor derived from the leptomeningeal melanocytes.
  • Although unusual, malignant transformation with leptomeningeal seeding into the brain or spinal cord may occur years after the initial diagnosis.
  • The authors report a unique case of multifocal benign meningeal melanocytoma involving both cerebellopontine angles and the thoracic spinal cord, with associated diffuse leptomeningeal hyperpigmentation.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellopontine Angle. Melanocytes / pathology. Melanoma / pathology. Meningeal Neoplasms / pathology. Neoplasm Seeding. Spinal Cord Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361258.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


35. Liu AK, Bagrosky B, Fenton LZ, Gaspar LE, Handler MH, McNatt SA, Foreman NK: Vascular abnormalities in pediatric craniopharyngioma patients treated with radiation therapy. Pediatr Blood Cancer; 2009 Feb;52(2):227-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Craniopharyngioma is a benign brain tumor that can be treated with some combination of surgery, intracystic chemotherapy and radiation therapy.
  • One had bilateral temporal cavernomas, one had moyamoya syndrome, one had an aneurysm of the internal carotid artery and three children had decreases in the caliber of the carotid or cerebral arteries, but were asymptomatic.

  • Genetic Alliance. consumer health - Craniopharyngioma.
  • MedlinePlus Health Information. consumer health - Vascular Diseases.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18937328.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 11056-06-7 / Bleomycin
  •  go-up   go-down


36. Della Puppa A, Rossetto M, Ciccarino P, Del Moro G, Rotilio A, Manara R, Paola Gardiman M, Denaro L, d'Avella D, Scienza R: The first 3 months after BCNU wafers implantation in high-grade glioma patients: clinical and radiological considerations on a clinical series. Acta Neurochir (Wien); 2010 Nov;152(11):1923-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In general, cysts presented a benign behaviour in the sense that patients promptly improved with corticosteroid treatment, never required surgery, never reported permanent neurological deficits.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Brain Neoplasms / drug therapy. Carmustine / administration & dosage. Glioma / drug therapy. Infusion Pumps, Implantable
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Neoplasm Recurrence, Local / radiography. Retrospective Studies

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. Carmustine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20703889.001).
  • [ISSN] 0942-0940
  • [Journal-full-title] Acta neurochirurgica
  • [ISO-abbreviation] Acta Neurochir (Wien)
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; U68WG3173Y / Carmustine
  •  go-up   go-down


37. Panagopoulos AT, Lancellotti CL, Veiga JC, de Aguiar PH, Colquhoun A: Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol; 2008 Aug;89(1):73-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas.
  • Most meningiomas are benign tumours of arachnoidal origin, although a small number have high proliferative rates and invasive properties which complicate complete surgical resection and are associated with increased recurrence rates.
  • Few prognostic indicators exist for meningiomas and further research is necessary to identify factors that influence tumour invasion, oedema and recurrence.
  • Paraffin sections from 25 intracranial meningiomas were analysed for expression of the proteins vascular endothelial growth factor (VEGF), VEGF receptors Flt1 and Flk1, E-cadherin, metalloproteinases 2 and 9 (MMP2, MMP9), CD44, receptor for hyaluronic acid-mediated motility (RHAMM), hyaluronic acid (HA), CD45, cyclooxygenase 2 (COX2), brain fatty acid binding protein (BFABP), Ki67, and proliferating cell nuclear antigen (PCNA).
  • COX2 expression increased with increasing with tumour grade and correlated with Ki67, PCNA, MI, MVD, and BFABP.
  • In conclusion Ki67, PCNA, MI, MVD, BFABP, and COX2 were significantly correlated with meningioma tumour grade and with each other.
  • These findings, by correlating both intracellular fatty acid transport and eicosanoid metabolism with tumour proliferation, as determined by Ki67 labelling and mitotic index, suggest fatty acids are involved in the progression of meningiomas.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / biosynthesis. Fatty Acids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neoplasm Proteins / biosynthesis. Neovascularization, Pathologic / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Acta Neuropathol. 1999 Sep;98(3):240-4 [10483780.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):529-38 [17016718.001]
  • [Cites] Neurosurg Focus. 2005 Nov 15;19(5):E9 [16398473.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):183-92; discussion 192-3 [12182416.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):508-17 [16235684.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4589-92 [11717317.001]
  • [Cites] Br J Neurosurg. 1998 Oct;12(5):414-8 [10070443.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):6-13 [14693827.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):235-45 [12510775.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Dec;32(6):674-8 [17083481.001]
  • [Cites] Neuroradiology. 1982;23 (4):207-9 [7121811.001]
  • [Cites] Cell Biol Int. 2006 Sep;30(9):704-13 [16829143.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):S98-102 [12902865.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Histopathology. 2006 Aug;49(2):178-87 [16879395.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 Feb;32(2):65-71 [1376862.001]
  • [Cites] Pathol Int. 2005 Jan;55(1):1-7 [15660696.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] BMC Cancer. 2006 Apr 19;6:97 [16623952.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] J Biochem Mol Biol. 2006 Sep 30;39(5):469-78 [17002866.001]
  • [Cites] J Cell Biol. 2006 Dec 18;175(6):1017-28 [17158951.001]
  • [Cites] Clinics (Sao Paulo). 2005 Jun;60(3):201-6 [15962080.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 6;330(2):489-97 [15796909.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):163-7 [9504862.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Br J Neurosurg. 1995;9(1):47-50 [7786426.001]
  • [Cites] Lung Cancer. 2006 Jul;53(1):91-6 [16697074.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Apr;30(2):118-25 [15043709.001]
  • [Cites] Trends Immunol. 2006 Mar;27(3):146-53 [16423560.001]
  • [Cites] J Histochem Cytochem. 1998 May;46(5):585-94 [9606106.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 Mar;27(3):460-8 [16788715.001]
  • [Cites] J Clin Neurosci. 2007 Apr;14(4):359-63 [17236775.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):29-37 [15015767.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1078-82 [12450029.001]
  • [Cites] Pathol Res Pract. 2006;202(5):365-72 [16563650.001]
  • [Cites] Childs Nerv Syst. 1995 Nov;11(11):661-3 [8608584.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):219-23 [15980972.001]
  • [Cites] Histopathology. 2006 Jun;48(7):836-45 [16722933.001]
  • [Cites] J Neurooncol. 2002 Nov;60(2):159-64 [12635663.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):19-30 [16078103.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Matrix Biol. 2007 Jan;26(1):58-68 [17055233.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10233-7 [17079438.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):936-44 [10091773.001]
  • [Cites] Stroke. 2006 Jun;37(6):1399-406 [16690896.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):483-8 [12478663.001]
  • [Cites] J Neurooncol. 2004 Dec;70(3):349-57 [15662977.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3962-5 [12124327.001]
  • [Cites] Clin Mol Pathol. 1996 Jun;49(3):M140-6 [16696062.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] J Appl Genet. 2006;47(1):39-48 [16424607.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1567-74 [10861283.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Epilepsy Res. 2000 Jan;38(1):45-52 [10604605.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):131-7 [16850103.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 18418552.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Eicosanoids; 0 / Fatty Acids; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


38. Qian ZY, Wu YY, Huang Q, Zhai DZ, Zhu Q, Wang AD, Huo HM, Lan Q: [Expression of SV40Tag, Rb and IRS-1 in glioma detected by tissue microarray and their relation with tumorigenesis and progression of gliomas]. Zhonghua Zhong Liu Za Zhi; 2008 Jun;30(6):432-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Tissue microarrays were constructed containing 118 samples including human glioma and meningioma, experimental glioma, and normal human brain tissue.
  • RESULTS: The expressions of SV40Tag, Rb and IRS-1 were detected in gliomas and benign brain tumors.
  • Their positive expression rate in glioma was 65.9%, 64.6% and 48.8%, respectively, with a statistically non-significant difference between the malignant and benign brain tumors.
  • In the normal human brain tissue only the expression of Rb (77.8%, 7/9) and IRS-1 (22.2%, 2/9) were detected, but expression of SV40Tag could not be observed.
  • CONCLUSION: Our findings that no expression of SV40Tag was observed in normal human brain tissue indicates that expression of SV40Tag may play an important role in the pathogenesis of glioma.
  • [MeSH-major] Antigens, Polyomavirus Transforming / metabolism. Brain Neoplasms / metabolism. Glioma / metabolism. Insulin Receptor Substrate Proteins / metabolism. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Brain / metabolism. Brain / pathology. Cell Line, Tumor. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Meningioma / metabolism. Meningioma / pathology. Mice. Middle Aged. Neoplasm Transplantation. Rats. Rats, Sprague-Dawley. Tissue Array Analysis. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19024517.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Polyomavirus Transforming; 0 / IRS1 protein, human; 0 / Insulin Receptor Substrate Proteins; 0 / Retinoblastoma Protein
  •  go-up   go-down


39. Utsuki S, Oka H, Sato Y, Kawano N, Tsuchiya B, Kobayashi I, Fujii K: Invasive meningioma is associated with a low expression of E-cadherin and beta-catenin. Clin Neuropathol; 2005 Jan-Feb;24(1):8-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Invasive meningioma shows benign histological features (WHO grade 1) and the brain expansion at the tumor-brain interface, and recurs more frequently than common meningiomas.
  • To determine the mechanism of brain expansion, we studied the relationship between invasive meningioma and cell adhesion molecules.
  • All tumors were negative for N-CH.
  • In invasive meningiomas, the expansive part of the tumor showed a lower rate (4/12 tumors) of E-CH and beta-catenin positivity, while the central part showed a higher rate (10/12 tumors).
  • [MeSH-major] Cadherins / metabolism. Cytoskeletal Proteins / metabolism. Meningeal Neoplasms / metabolism. Meningeal Neoplasms / pathology. Meningioma / metabolism. Meningioma / pathology. Trans-Activators / metabolism
  • [MeSH-minor] Humans. Immunologic Techniques. Ki-67 Antigen / metabolism. Neoplasm Invasiveness. Staining and Labeling. beta Catenin

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15696778.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / CTNNB1 protein, human; 0 / Cadherins; 0 / Cytoskeletal Proteins; 0 / Ki-67 Antigen; 0 / Trans-Activators; 0 / beta Catenin
  •  go-up   go-down


40. Asioli S, Senetta R, Maldi E, D'Ambrosio E, Satolli MA, Bussolati G, Cassoni P: "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung. Virchows Arch; 2007 May;450(5):591-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Benign" metastatic meningioma: clinico-pathological analysis of one case metastasising to the lung and overview on the concepts of either primitive or metastatic meningiomas of the lung.
  • Lung "metastases" of benign meningiomas are rarely described events of biological and clinical interest.
  • Anamnesis revealed that the patient underwent a surgical resection of cerebral meningioma 12 years before.
  • The morphological and immunohistochemical features of this lesion, together with the similarity with the original cerebral tumour and its indolent evolution, led to a final diagnosis of "benign" meningioma metastatic to the lung.
  • They represent a typical example of "benign" tumours that may implant to the lung similar to other tumours, definitely considered benign but reported to rarely present unusual secondary localization.
  • [MeSH-major] Brain Neoplasms / pathology. Lung Neoplasms / secondary. Meningioma / secondary
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Female. Humans. Neoplasm Metastasis / pathology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1991 Mar 1;67(5):1412-7 [1991305.001]
  • [Cites] AJNR Am J Neuroradiol. 1987 Jan-Feb;8(1):127-30 [3101455.001]
  • [Cites] Virchows Arch. 2001 Aug;439(2):196-200 [11561761.001]
  • [Cites] Am J Surg Pathol. 1997 Aug;21(8):976 [9255263.001]
  • [Cites] J Neurosurg. 2003 Jan;98(1):194-8 [12546373.001]
  • [Cites] J Neurosurg. 1985 May;62(5):763-6 [3989597.001]
  • [Cites] Arch Pathol Lab Med. 1997 Jun;121(6):631-6 [9199633.001]
  • [Cites] Semin Diagn Pathol. 1995 May;12(2):193-206 [7638451.001]
  • [Cites] J Thorac Imaging. 2002 Jul;17 (3):227-9 [12082375.001]
  • [Cites] Clin Neurol Neurosurg. 1990;92(2):152-4 [2163798.001]
  • [Cites] Am J Surg Pathol. 2004 Feb;28(2):207-14 [15043310.001]
  • [Cites] J Cutan Pathol. 1987 Jun;14(3):129-46 [3301927.001]
  • [Cites] Adv Clin Path. 2000 Jan;4(1):35-9 [10936897.001]
  • [Cites] Am J Surg Pathol. 1988 Mar;12(3):167-75 [2830799.001]
  • [Cites] J Laryngol Otol. 2004 Sep;118(9):724-6 [15509374.001]
  • [Cites] J Comput Assist Tomogr. 2001 Mar-Apr;25(2):311-3 [11242234.001]
  • [Cites] Neurosurgery. 1992 Dec;31(6):1113-6; discussion 1116 [1470323.001]
  • [Cites] Dtsch Med Wochenschr. 2004 Sep 3;129(36):1854-7 [15368156.001]
  • [Cites] Am J Clin Oncol. 2001 Dec;24(6):579-82 [11801758.001]
  • [Cites] Ann Thorac Surg. 1996 Jun;61(6):1823-4 [8651794.001]
  • [Cites] Hum Pathol. 1991 May;22(5):469-74 [1709609.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1999 Aug;88(2):170-6 [10468461.001]
  • [Cites] Neurosurgery. 1987 May;20(5):688-94 [3601014.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):453-60 [9130993.001]
  • [Cites] Clin Orthop Relat Res. 1988 Dec;(237):275-85 [3056645.001]
  • [Cites] Hum Pathol. 1999 Apr;30(4):425-9 [10208464.001]
  • [Cites] Surg Neurol. 1988 May;29(5):410-3 [3363477.001]
  • [Cites] Jpn J Clin Oncol. 2003 Feb;33(2):86-8 [12629059.001]
  • (PMID = 17431673.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


41. McCall T, Chin SS, Salzman KL, Fults DW: Tuberous sclerosis: a syndrome of incomplete tumor suppression. Neurosurg Focus; 2006;20(1):E3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tuberous sclerosis: a syndrome of incomplete tumor suppression.
  • The latter is a benign brain tumor of mixed neuronal and glial origin.
  • [MeSH-major] Hamartoma / complications. Tuberous Sclerosis / etiology. Tuberous Sclerosis / genetics. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Animals. Brain Neoplasms / complications. Brain Neoplasms / genetics. Humans. Models, Biological

  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Tuberous Sclerosis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16459993.001).
  • [ISSN] 1092-0684
  • [Journal-full-title] Neurosurgical focus
  • [ISO-abbreviation] Neurosurg Focus
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; 0 / tuberous sclerosis complex 1 protein; 4JG2LF96VF / tuberous sclerosis complex 2 protein
  • [Number-of-references] 92
  •  go-up   go-down


42. Pulukuri SM, Estes N, Patel J, Rao JS: Demethylation-linked activation of urokinase plasminogen activator is involved in progression of prostate cancer. Cancer Res; 2007 Feb 1;67(3):930-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we show that uPA is aberrantly expressed in a high percentage of human prostate cancer tissues but rarely expressed either in tumor-matched nonneoplastic adjacent tissues or benign prostatic hyperplasia samples.
  • Furthermore, treatment with demethylation inhibitor S-adenosylmethionine or stable expression of uPA short hairpin RNA significantly inhibits uPA expression and tumor cell invasion in vitro and tumor growth and incidence of lung metastasis in vivo.
  • Collectively, these findings strongly suggest that DNA demethylation is a common mechanism underlying the abnormal expression of uPA and is a critical contributing factor to the malignant progression of human prostate tumors.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2003 Jan-Feb;53(1):5-26 [12568441.001]
  • [Cites] Int J Oncol. 2003 Feb;22(2):289-94 [12527924.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1684-95 [12670923.001]
  • [Cites] FASEB J. 2003 Jun;17(9):1081-8 [12773490.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20812-20 [12676953.001]
  • [Cites] Nat Rev Cancer. 2003 Jul;3(7):489-501 [12835669.001]
  • [Cites] Oncogene. 2003 Sep 4;22(38):5967-75 [12955075.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3035-41 [15131040.001]
  • [Cites] Mol Cancer Ther. 2004 Jun;3(6):671-8 [15210852.001]
  • [Cites] J Biol Chem. 2004 Jul 23;279(30):31735-44 [15150277.001]
  • [Cites] Reprod Biol Endocrinol. 2004 Jan 7;2:2 [14711377.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):33613-22 [15150279.001]
  • [Cites] J Cell Biol. 1984 Aug;99(2):753-7 [6378927.001]
  • [Cites] J Urol. 1988 Dec;140(6):1466-9 [3193516.001]
  • [Cites] J Urol. 1989 Jul;142(1):193-8 [2659823.001]
  • [Cites] Carcinogenesis. 1989 Jul;10(7):1183-92 [2472229.001]
  • [Cites] Cancer Res. 1990 Oct 1;50(19):6130-8 [1698118.001]
  • [Cites] Prostate. 1991;18(3):201-14 [1902292.001]
  • [Cites] Am J Pathol. 1991 May;138(5):1059-67 [1850957.001]
  • [Cites] Cancer Commun. 1991 Aug;3(8):255-64 [1653586.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3656-61 [8033079.001]
  • [Cites] Gynecol Oncol. 1994 Dec;55(3 Pt 1):401-9 [7835780.001]
  • [Cites] Am J Pathol. 1995 Jul;147(1):114-23 [7604873.001]
  • [Cites] Am J Med Sci. 1996 Jul;312(1):8-11 [8686732.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Int J Oncol. 1999 Mar;14(3):535-41 [10024688.001]
  • [Cites] APMIS. 1999 Jan;107(1):150-9 [10190292.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8743-50 [15623660.001]
  • [Cites] Clin Prostate Cancer. 2004 Dec;3(3):150-6 [15636681.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1028-36 [15709168.001]
  • [Cites] Cancer Res. 2005 Mar 15;65(6):2115-24 [15781621.001]
  • [Cites] Cancer Res. 2005 May 15;65(10):4218-27 [15899813.001]
  • [Cites] Biochemistry (Mosc). 2005 May;70(5):533-49 [15948707.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5793-801 [16115918.001]
  • [Cites] Clin Cancer Res. 2005 Aug 15;11(16):5869-77 [16115928.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7635-43 [16140929.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):36529-40 [16127174.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):327-41 [16389945.001]
  • [Cites] Oncogene. 2006 Aug 3;25(33):4559-72 [16786000.001]
  • [Cites] Hum Pathol. 2000 May;31(5):578-83 [10836297.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Sep 1;48(2):507-12 [10974469.001]
  • [Cites] Int J Cancer. 2000 Sep 20;89(5):431-9 [11008205.001]
  • [Cites] J Natl Cancer Inst. 2000 Nov 1;92(21):1717-30 [11058615.001]
  • [Cites] Int J Oncol. 2001 Jan;18(1):71-9 [11115541.001]
  • [Cites] Exp Cell Res. 2001 Apr 1;264(2):326-36 [11262189.001]
  • [Cites] J Urol. 2002 Feb;167(2 Pt 1):528-34 [11792912.001]
  • [Cites] Nat Rev Mol Cell Biol. 2002 Dec;3(12):932-43 [12461559.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1232-7 [12663709.001]
  • (PMID = 17283123.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / NS 47699; United States / NCI NIH HHS / CA / R01 CA075557; United States / NINDS NIH HHS / NS / NS 57529; United States / NCI NIH HHS / CA / CA 75557; United States / NCI NIH HHS / CA / CA 92393; United States / NCI NIH HHS / CA / CA 95058; United States / NCI NIH HHS / CA / R01 CA116708; United States / NINDS NIH HHS / NS / R01 NS047699; United States / NCI NIH HHS / CA / R01 CA095058; United States / NCI NIH HHS / CA / R01 CA092393; United States / NCI NIH HHS / CA / CA 116708
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 7LP2MPO46S / S-Adenosylmethionine; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator
  • [Other-IDs] NLM/ NIHMS14046; NLM/ PMC1832148
  •  go-up   go-down


43. Ganesan K, Desai S, Udwadia-Hegde A: Non-infantile variant of desmoplastic ganglioglioma: a report of 2 cases. Pediatr Radiol; 2006 Jun;36(6):541-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Desmoplastic infantile gangliogliomas (DIGs) are uncommon supratentorial brain tumors with a usually good prognosis despite an aggressive radiological appearance.
  • These tumors form part of a spectrum of desmoplastic infantile tumors that includes desmoplastic infantile astrocytomas.
  • DIGs are classified as benign WHO grade I tumors of infancy.
  • Non-infantile variants of this biologically benign intracranial neoplasm are rare, with only four previous case reports in the literature.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology


44. Arai A, Sasayama T, Tamaki M, Sakagami Y, Enoki E, Ohbayashi C, Kohmura E: Rosette-forming glioneuronal tumor of the fourth ventricle--case report. Neurol Med Chir (Tokyo); 2010;50(3):224-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rosette-forming glioneuronal tumor of the fourth ventricle--case report.
  • Rosette-forming glioneuronal tumor (RGNT) of the fourth ventricle is a rare tumor included as a novel glioneuronal neoplasm in the 2007 World Health Organization classification of brain tumors.
  • The tumor was gross totally resected.
  • RGNT of the fourth ventricle should be considered in the differential diagnosis of infratentorial lesions in young adults.
  • The prognosis is benign, but relatively aggressive behaviors such as tumor growth, recurrence, and acute deterioration due to intratumoral hemorrhaging can occur.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Fourth Ventricle / pathology. Infratentorial Neoplasms / pathology. Neoplasms, Neuroepithelial / pathology. Teratoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20339273.001).
  • [ISSN] 1349-8029
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


45. Suehiro K, Pritzwald-Stegmann P, Lee KM, Teoh HH, Alison PM: Mediastinal and pulmonary metastases of malignant ossifying fibromyxoid tumor. Ann Thorac Surg; 2006 Jun;81(6):2289-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mediastinal and pulmonary metastases of malignant ossifying fibromyxoid tumor.
  • Ossifying fibromyxoid tumor is usually a benign tumor.
  • However some of these tumors with histologic and clinical evidence of malignancy have also been reported and little information is available regarding surgery for metastatic ossifying fibromyxoid tumor.
  • We present a case involving extensive excision of a huge metastatic ossifying fibromyxoid tumor occupying the upper mediastinum and upper half of the right hemithorax.
  • [MeSH-major] Fibroma, Ossifying / pathology. Lung Neoplasms / secondary. Mediastinal Neoplasms / secondary
  • [MeSH-minor] Adult. Brain Neoplasms / complications. Brain Neoplasms / secondary. Diagnostic Errors. Fatal Outcome. Female. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / surgery. Humans. Lipoma / diagnosis. Neoplasm Invasiveness. Pericardium / pathology. Pericardium / surgery. Phrenic Nerve / pathology. Phrenic Nerve / surgery. Pneumonectomy. Radiotherapy, Adjuvant. Reoperation. Seizures / etiology. Skin Neoplasms / pathology. Skin Neoplasms / surgery. Superior Vena Cava Syndrome / etiology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16731174.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


46. Gunny RS, Hayward RD, Phipps KP, Harding BN, Saunders DE: Spontaneous regression of residual low-grade cerebellar pilocytic astrocytomas in children. Pediatr Radiol; 2005 Nov;35(11):1086-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cerebellar low-grade astrocytomas (CLGAs) of childhood are benign tumours and are usually curable by surgical resection alone or combined with adjuvant radiotherapy.
  • In this report we describe the phenomenon of spontaneous regression of residual tumour and discuss its prognostic significance regarding future imaging.
  • Spontaneous tumour regression was seen in 5 (45.5%) of the 11 children.
  • There were no differences in age, gender, symptomatology, histological grade or Ki-67 fractions between those with spontaneous tumour regression and those with progression.
  • CONCLUSIONS: Residual tumour followed by surveillance imaging may either regress or progress.
  • For children with residual disease we recommend surveillance imaging every 6 months for the first 2 years, every year for years 3, 4 and 5, then every second year if residual tumour is still present 5 years after initial surgery.
  • [MeSH-major] Astrocytoma / pathology. Cerebellar Neoplasms / pathology. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / pathology. Neoplasm Regression, Spontaneous / pathology. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Childs Nerv Syst. 1997 Jan;13(1):17-23 [9083697.001]
  • [Cites] Childs Nerv Syst. 1998 Nov;14 (11):636-48 [9840364.001]
  • [Cites] Neurosurgery. 1992 Jan;30(1):58-62; discussion 62-3 [1738456.001]
  • [Cites] J Neurooncol. 1999 Apr;42(2):143-50 [10421072.001]
  • [Cites] Can J Neurol Sci. 1985 Feb;12 (1):75 [3978477.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):265-73 [9950497.001]
  • [Cites] Neuroradiology. 1999 Mar;41(3):199-201 [10206167.001]
  • [Cites] Pediatr Neurosurg. 2000 Mar;32(3):132-6 [10867559.001]
  • [Cites] Neurosurgery. 1984 Sep;15(3):421-3 [6435008.001]
  • [Cites] J Neuropathol Exp Neurol. 1998 Oct;57(10):931-6 [9786243.001]
  • [Cites] J Neurooncol. 1998 Mar;37(1):9-16 [9525833.001]
  • [Cites] J Neurosurg. 2001 Jan;94(1):27-32 [11147894.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):544-53; discussion 554-5 [12943571.001]
  • [Cites] Neurosurgery. 1994 Aug;35(2):342-3 [7969850.001]
  • [Cites] Childs Nerv Syst. 1995 Feb;11(2):89-96 [7758018.001]
  • [Cites] Arch Ophthalmol. 2001 Apr;119(4):516-29 [11296017.001]
  • [Cites] AJNR Am J Neuroradiol. 1999 Sep;20(8):1547-53 [10512244.001]
  • [Cites] Pediatr Neurosurg. 2002 Aug;37(2):71-80 [12145515.001]
  • [Cites] Neurosurgery. 1998 Apr;42(4):724-9 [9574635.001]
  • [Cites] J Neurosurg. 2003 Aug;99(2):280-6 [12924701.001]
  • [Cites] Clin Oncol (R Coll Radiol). 1999;11(5):290-4 [10591817.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1981 Sep;44(9):820-8 [7310422.001]
  • [Cites] Neurosurgery. 1984 Sep;15(3):315-7 [6483145.001]
  • [Cites] AJNR Am J Neuroradiol. 1998 Jan;19(1):151-6 [9432173.001]
  • [Cites] N Engl J Med. 1995 Dec 28;333(26):1757-63 [7491141.001]
  • [Cites] Br J Cancer. 2003 Jul 7;89(1):128-34 [12838313.001]
  • [Cites] J Neurosurg. 2005 Mar;102(2 Suppl):172-8 [16156227.001]
  • [Cites] J Neurosurg Sci. 1994 Jun;38(2):131-5 [7891195.001]
  • [Cites] AJNR Am J Neuroradiol. 1993 Jan-Feb;14 (1):77-87 [8381255.001]
  • [Cites] Br J Neurosurg. 1998 Aug;12(4):318-24 [10070423.001]
  • [Cites] Clin Med Res. 2004 May;2(2):85-8 [15931340.001]
  • [Cites] Cancer. 1996 Jan 15;77(2):373-80 [8625247.001]
  • [Cites] Brain. 1982 Mar;105(Pt 1):161-87 [7066671.001]
  • [Cites] Pediatr Neurosurg. 2001 Dec;35(6):311-7 [11786699.001]
  • (PMID = 16047140.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


47. Zou M, Al-Baradie RS, Al-Hindi H, Farid NR, Shi Y: S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma. Br J Cancer; 2005 Nov 28;93(11):1277-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumour cell invasion and metastasis are the hallmark of malignant neoplasm.
  • To further determine whether S100A4 overexpression is associated with thyroid tumour invasion and metastasis, in the present study, we examined S100A4 gene expression in six benign multinodular goitres (MNG) and 28 matched samples of adjacent normal thyroid tissue (N), primary (T) and metastatic (M) papillary thyroid carcinomas (PTC) by immunohistochemistry and real-time reverse transcription-polymerase chain reaction (RT-PCR) analysis.
  • These data suggest that overexpression of S100A4 is associated with thyroid tumour invasion and metastasis and it may be a potential target for therapeutic intervention.
  • [MeSH-minor] Case-Control Studies. Gene Expression Profiling. Goiter / genetics. Goiter / pathology. Humans. Immunohistochemistry. Neoplasm Invasiveness. Neoplasm Metastasis. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] APMIS. 2003 May;111(5):539-45 [12887505.001]
  • [Cites] Brain Res. 2000 Jun 9;867(1-2):280-8 [10837826.001]
  • [Cites] J Biol Chem. 2003 Sep 5;278(36):33809-17 [12777394.001]
  • [Cites] Biochemistry. 2003 Dec 9;42(48):14258-66 [14640694.001]
  • [Cites] Br J Cancer. 2004 Jan 12;90(1):253-62 [14710237.001]
  • [Cites] Oral Oncol. 2004 May;40(5):496-500 [15006621.001]
  • [Cites] Oncogene. 2004 Apr 29;23(20):3670-80 [15116098.001]
  • [Cites] Clin Biochem. 2004 Jul;37(7):512-8 [15234232.001]
  • [Cites] J Biol Chem. 2004 Aug 6;279(32):34071-7 [15178678.001]
  • [Cites] Br J Cancer. 2004 Aug 16;91(4):739-44 [15280928.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5564-9 [15313892.001]
  • [Cites] J Neurosci Res. 2004 Sep 15;77(6):777-86 [15334597.001]
  • [Cites] Oncology. 2004;66(6):429-38 [15452371.001]
  • [Cites] Cancer Res. 1991 May 15;51(10):2690-3 [2021946.001]
  • [Cites] Br J Cancer. 1992 Jun;65(6):832-7 [1352125.001]
  • [Cites] Genomics. 1995 Feb 10;25(3):638-43 [7759097.001]
  • [Cites] DNA Cell Biol. 1995 Oct;14(10):825-32 [7546288.001]
  • [Cites] Endocrinol Metab Clin North Am. 1995 Dec;24(4):865-83 [8608782.001]
  • [Cites] Oncogene. 1996 Oct 17;13(8):1631-7 [8895508.001]
  • [Cites] Oncogene. 1997 Jan 23;14(3):331-7 [9018119.001]
  • [Cites] Cancer. 1997 Oct 15;80(8 Suppl):1529-37 [9362419.001]
  • [Cites] Biochemistry. 1997 Dec 23;36(51):16321-7 [9405067.001]
  • [Cites] Oncogene. 1998 Jul 30;17(4):465-73 [9696040.001]
  • [Cites] Clin Cancer Res. 1997 Dec;3(12 Pt 1):2309-16 [9815629.001]
  • [Cites] Biochim Biophys Acta. 1998 Dec 10;1448(2):190-9 [9920410.001]
  • [Cites] Clin Exp Metastasis. 1998 Jul;16(5):471-9 [10091942.001]
  • [Cites] Br J Cancer. 1999 Mar;79(7-8):1234-9 [10098765.001]
  • [Cites] Thyroid. 1999 May;9(5):421-7 [10365671.001]
  • [Cites] Eur J Cancer. 1999 Mar;35(3):467-72 [10448301.001]
  • [Cites] Neurochem Res. 1999 Sep;24(9):1097-100 [10485579.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4702-8 [10493528.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Dec;89(12):6146-54 [15579771.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1455-60 [15608681.001]
  • [Cites] Oncogene. 2005 Feb 17;24(8):1445-54 [15608682.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Aug 11;274(3):865-71 [10924368.001]
  • [Cites] Clin Cancer Res. 2000 Nov;6(11):4234-42 [11106237.001]
  • [Cites] Int J Oncol. 2001 Apr;18(4):715-20 [11251165.001]
  • [Cites] Nature. 2001 May 17;411(6835):375-9 [11357145.001]
  • [Cites] Int J Biochem Cell Biol. 2001 Jul;33(7):637-68 [11390274.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Sep;32(1):43-9 [11477660.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13889-94 [11717446.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):7-13 [11786392.001]
  • [Cites] Am J Pathol. 2002 Jan;160(1):45-50 [11786397.001]
  • [Cites] Methods Mol Biol. 2002;172:69-80 [11833360.001]
  • [Cites] Br J Cancer. 2002 Feb 1;86(3):409-16 [11875708.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(8):2821-9 [11909974.001]
  • [Cites] Front Biosci. 2002 May 1;7:d1356-68 [11991838.001]
  • [Cites] Curr Opin Oncol. 2003 Jan;15(1):71-7 [12490765.001]
  • [Cites] Lancet. 2003 Feb 8;361(9356):501-11 [12583960.001]
  • [Cites] Histopathology. 2005 Mar;46(3):256-69 [15720411.001]
  • [Cites] Virchows Arch. 2003 Apr;442(4):322-8 [12715168.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Brain Res. 2000 Mar 6;858(1):121-8 [10700604.001]
  • [Cites] Cancer Res. 2000 Mar 15;60(6):1595-603 [10749128.001]
  • [Cites] J Pathol. 2003 Aug;200(5):589-95 [12898594.001]
  • (PMID = 16265347.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / S100 Proteins; 142662-27-9 / S100A4 protein, human
  • [Other-IDs] NLM/ PMC2361511
  •  go-up   go-down


48. Zhi L, Bing L, Yang L, Bo-ning L, Quan H: Cystic papillary meningioma with subarachnoid dissemination: a case report and review of the literature. Pathol Res Pract; 2009;205(8):582-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningiomas usually present as benign tumors corresponding to WHO grade I.
  • We report a case of cystic papillary meningioma in a young female occurring in the lateral ventricle with invasion of brain parenchyma and dissemination of subarachnoid space.
  • The tumor exhibits a marked peritumoral cyst, with contrast enhancement on magnetic resonance imaging (MRI) in accordance with type 2 of Zee's classification of cystic meningioma.
  • Histologically, the tumor displays a classical perivascular pseudopapillary pattern with focal necrosis and subarachnoid space dissemination.
  • Tumor cells are diffusely positive for epithelial membrane antigen (EMA) and vimentin, but lack immunoreactivity for cytokeratin (CK) and glial fibrillary acidic protein (GFAP).
  • MIB-1 labeling is high, accounting for 5% of tumor focally.
  • A diagnosis of primary intraventricular cystic papillary meningioma with subarachnoid space dissemination (WHO grade III) was made.
  • In addition, the biological behavior and the clinical outcome of this tumor are also discussed.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Cysts / pathology. Meningeal Neoplasms / pathology. Meningioma / pathology
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Female. Humans. Magnetic Resonance Imaging. Mucin-1 / metabolism. Neoplasm Staging. Treatment Outcome. Vimentin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Meningioma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19307065.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Mucin-1; 0 / Vimentin
  •  go-up   go-down


49. Valentí V, López-Pousa A, Gonzalez Y, Farré N: Radiation-induced mandibular osteogenic sarcoma: report of a case and review of the literature. J Craniofac Surg; 2005 May;16(3):452-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Radiation-induced sarcomas are uncommon tumors that are diagnosed by meeting some diagnostic criteria.
  • The authors have found in the literature 30 cases of mandibular radiation-induced osteogenic sarcomas, most of them secondary to treatment of benign lesions, none of them secondary to treatment of a laryngeal cancer, as was seen in their case.
  • [MeSH-major] Cranial Irradiation / adverse effects. Mandibular Neoplasms / etiology. Neoplasms, Radiation-Induced / surgery. Osteosarcoma / etiology
  • [MeSH-minor] Brain Neoplasms / secondary. Carcinoma, Squamous Cell / radiotherapy. Fatal Outcome. Humans. Laryngeal Neoplasms / radiotherapy. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15915114.001).
  • [ISSN] 1049-2275
  • [Journal-full-title] The Journal of craniofacial surgery
  • [ISO-abbreviation] J Craniofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Hargrave D: Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy. Br J Neurosurg; 2009 Aug;23(4):351-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Paediatric high and low grade glioma: the impact of tumour biology on current and future therapy.
  • Gliomas are the most common type of paediatric brain tumour and range from benign low grade gliomas which can be resected/observed to aggressive brainstem gliomas with dismal survival rates.
  • Pilocytic astrocytoma, the most common childhood low grade brain tumour, has recently been shown to harbour an activated BRAF/MAPK/ERK pathway in the majority of cases; this represents an attractive target for new agents.
  • Brainstem glioma remains a tumour with a dismal prognosis but relatively little is known about the underlying biology and progress will require a concerted effort to collect tissue by biopsy and autopsy to allow appropriate analysis to identify and validate targets.
  • [MeSH-major] Brain Neoplasms. Glioma / pathology
  • [MeSH-minor] Adolescent. Adult. Astrocytoma / genetics. Astrocytoma / pathology. Astrocytoma / therapy. Child. Child, Preschool. Combined Modality Therapy. Drug Delivery Systems. Genetic Predisposition to Disease. Genome-Wide Association Study. Hamartoma Syndrome, Multiple / genetics. Humans. Infant. Neoplasm Staging. Neurofibromatosis 1 / genetics. Prognosis. Tuberous Sclerosis / genetics


51. Soudack M, Guralnik L, Ben-Nun A, Berkowitz D, Postovsky S, Vlodavsky E, Engel A: Imaging features of posterior mediastinal chordoma in a child. Pediatr Radiol; 2007 May;37(5):492-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Evaluation by CT revealed a low-density posterior mediastinal mass initially diagnosed as benign tumor.
  • We present our suggestions for preoperative evaluation of posterior mediastinal tumors.
  • [MeSH-major] Chordoma / diagnosis. Mediastinal Neoplasms / diagnosis. Mediastinum / diagnostic imaging. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Child, Preschool. Cough / etiology. Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Respiratory Sounds. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Chordoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Hematol Oncol. 2003 Sep;25(9):743-6 [12972813.001]
  • [Cites] J Pediatr Surg. 1992 Dec;27(12 ):1515-8 [1469556.001]
  • [Cites] AJR Am J Roentgenol. 1996 Jan;166(1):26-7 [8571897.001]
  • [Cites] J Thorac Cardiovasc Surg. 1972 Jun;63(6):922-4 [5028681.001]
  • [Cites] Cancer. 1967 Nov;20(11):1841-50 [6061621.001]
  • [Cites] Hum Pathol. 1995 Dec;26(12):1354-62 [8522309.001]
  • [Cites] Spine (Phila Pa 1976). 1983 Oct;8(7):781-6 [6665580.001]
  • [Cites] Skeletal Radiol. 1980;5(3):171-3 [7209569.001]
  • [Cites] J Pediatr Surg. 2002 Jan;37(1):50-6 [11781986.001]
  • [Cites] Childs Brain. 1981;8(3):198-206 [7238137.001]
  • [Cites] Skeletal Radiol. 2003 Jun;32(6):343-50 [12719927.001]
  • [Cites] Neurol Med Chir (Tokyo). 2002 Apr;42(4):175-80 [12013671.001]
  • [Cites] Arch Pathol Lab Med. 1993 Sep;117(9):927-33 [8368907.001]
  • [Cites] J Fr Med Chir Thorac. 1961 Aug-Sep;15:623-31 [13873536.001]
  • [Cites] Eur J Cardiothorac Surg. 2003 Feb;23 (2):248-50 [12559357.001]
  • (PMID = 17345078.001).
  • [ISSN] 0301-0449
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


52. Fassett DR, Pingree J, Kestle JR: The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature. J Neurosurg; 2005 Jan;102(1 Suppl):59-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature.
  • Myxopapillary ependymomas (MPEs) have historically been thought to be benign tumors occurring most frequently in adults.
  • Only 8 to 20% of these tumors occur in the first two decades of life, making this tumor a rarity in pediatric neurosurgery.
  • In those cases in which patients underwent screening for CNS tumor dissemination, however, the incidence of disseminated disease was 58% (seven of 12 patients).
  • In pediatric patients MPEs may spread throughout the CNS via cerebrospinal fluid pathways; therefore, MR imaging of the entire CNS axis is recommended at both presentation and follow-up review to detect tumor dissemination.
  • [MeSH-major] Brain Neoplasms / secondary. Ependymoma / pathology. Ependymoma / secondary. Neoplasm Metastasis. Spinal Cord Neoplasms / pathology


53. van der Meij JJ, Boomars KA, van den Bosch JM, van Boven WJ, de Bruin PC, Seldenrijk CA: Primary pulmonary malignant meningioma. Ann Thorac Surg; 2005 Oct;80(4):1523-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary pulmonary meningiomas are relatively rare and mostly benign.
  • To exclude pulmonary metastasis of an intracranial meningioma, imaging studies of the brain should be performed.
  • We believe that only one primary pulmonary malignant meningioma in which a metastasis from the brain was excluded has been reported.
  • [MeSH-major] Bronchial Neoplasms / diagnosis. Bronchial Neoplasms / pathology. Meningioma / diagnosis. Meningioma / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Esophageal Neoplasms / pathology. Female. Humans. Liver Neoplasms / secondary. Magnetic Resonance Imaging. Meningeal Neoplasms / diagnosis. Neoplasm Invasiveness. Pleural Neoplasms / pathology. Treatment Outcome

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16181912.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


54. Vladimirova V, Mikeska T, Waha A, Soerensen N, Xu J, Reynolds PC, Pietsch T: Aberrant methylation and reduced expression of LHX9 in malignant gliomas of childhood. Neoplasia; 2009 Jul;11(7):700-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-grade gliomas (HGGs) of childhood represent approximately 7% of pediatric brain tumors.
  • They are highly invasive tumors and respond poorly to conventional treatments in contrast to pilocytic astrocytomas, which usually are well demarcated and frequently can be cured by surgery.
  • In the current study, to identify aberrantly methylated genes that may be involved in the tumorigenesis of pediatric HGGs, we performed a microarray-based differential methylation hybridization approach and found frequent hypermethylation of the LHX9 (human Lim-homebox 9) gene encoding a transcription factor involved in brain development.
  • Bisulfite genomic sequencing and combined bisulfite restriction analysis showed that HGGs were frequently methylated at two CpG-rich LHX9 regions in comparison to benign, nondiffuse pilocytic astrocytomas and normal brain tissues.
  • [MeSH-major] Brain Neoplasms / genetics. DNA Methylation / genetics. Glioma / genetics. Homeodomain Proteins / genetics
  • [MeSH-minor] Adolescent. Apoptosis / genetics. Base Sequence. Blotting, Western. Cell Movement / genetics. Cell Proliferation. Child. Child, Preschool. Humans. LIM-Homeodomain Proteins. Microarray Analysis. Molecular Sequence Data. Neoplasm Invasiveness / genetics. RNA, Messenger / analysis. Reverse Transcriptase Polymerase Chain Reaction. Transcription Factors

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 2000;17(2):49-56 [11210171.001]
  • [Cites] Genomics. 2000 Mar 15;64(3):307-17 [10756098.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6885-91 [11559565.001]
  • [Cites] Cancer Res. 2001 Dec 1;61(23):8375-80 [11731411.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):275-81 [11895042.001]
  • [Cites] Cancer Res. 2002 Apr 1;62(7):2085-91 [11929829.001]
  • [Cites] Oncogene. 2002 Aug 12;21(35):5496-503 [12154410.001]
  • [Cites] Front Biosci. 2003 Jan 1;8:s175-84 [12456310.001]
  • [Cites] Gene Expr Patterns. 2002 Dec;2(3-4):373-7 [12617828.001]
  • [Cites] Nat Rev Cancer. 2004 Sep;4(9):707-17 [15343277.001]
  • [Cites] Am J Pathol. 2004 Oct;165(4):1151-61 [15466382.001]
  • [Cites] Trends Genet. 1994 Sep;10(9):315-20 [7974745.001]
  • [Cites] C R Acad Sci III. 1995 Mar;318(3):295-306 [7788499.001]
  • [Cites] Nucleic Acids Res. 1997 Jun 15;25(12):2532-4 [9171110.001]
  • [Cites] Brain Pathol. 1998 Jan;8(1):13-8 [9458162.001]
  • [Cites] Bioessays. 1998 Jan;20(1):58-69 [9504048.001]
  • [Cites] J Neurosci. 1999 Jan 15;19(2):783-93 [9880598.001]
  • [Cites] Hum Mol Genet. 1999 Mar;8(3):459-70 [9949205.001]
  • [Cites] Bioinformatics. 1999 May;15(5):356-61 [10366655.001]
  • [Cites] Curr Opin Genet Dev. 2005 Feb;15(1):87-96 [15661538.001]
  • [Cites] Cancer Res. 2005 Jan 1;65(1):76-84 [15665281.001]
  • [Cites] Neoplasia. 2005 Jan;7(1):7-16 [15720813.001]
  • [Cites] Neoplasia. 2005 Mar;7(3):193-9 [15799819.001]
  • [Cites] Bioinformatics. 2005 Nov 1;21(21):4067-8 [16141249.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7490-501 [16885346.001]
  • [Cites] Oncogene. 2006 Aug 17;25(36):5018-26 [16732332.001]
  • [Cites] J Neurooncol. 2006 Sep;79(3):315-21 [16645718.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):890-900 [17283119.001]
  • [Cites] J Mol Diagn. 2007 Jul;9(3):368-81 [17591937.001]
  • [Cites] Mol Vis. 2007;13:1483-95 [17893672.001]
  • [Cites] Am J Pathol. 2001 Apr;158(4):1525-32 [11290570.001]
  • (PMID = 19568415.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / LHX9 protein, human; 0 / LIM-Homeodomain Proteins; 0 / RNA, Messenger; 0 / Transcription Factors
  • [Other-IDs] NLM/ PMC2697356
  •  go-up   go-down


55. Badr El-Din NK, Settin A, Ali N, Abdel-Hady el-SK, Salem FK: Cytokine gene polymorphisms in egyptian cases with brain tumors. J Egypt Natl Canc Inst; 2009 Jun;21(2):101-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytokine gene polymorphisms in egyptian cases with brain tumors.
  • BACKGROUND: Cytokines are proposed to play important roles in brain tumor biology as well as neurodegeneration or impaired neuronal function.
  • OBJECTIVES: This work aimed to check the association of polymorphisms of cytokine genes in Egyptian cases with brain tumors.
  • METHODS: This work included 45 cases affected by brain tumors diagnosed as 24 benign and 21 malignant.
  • RESULTS: Cases affected with benign brain tumors showed a significant higher frequency of IL-10-1082 A/A [odds ratio (OR=8.0), p<0.001] and IL-6-174 C/C (OR=6.3, p=0.002) homozygous genotypes as compared to controls.
  • CONCLUSIONS: Cytokine gene polymorphisms showed a pattern of association with brain tumors which may have potential impact on family counseling and disease management.
  • [MeSH-major] Biomarkers, Tumor / genetics. Brain Neoplasms / genetics. Cytokines / genetics. Polymorphism, Genetic / genetics
  • [MeSH-minor] Case-Control Studies. DNA / genetics. Egypt. Female. Genotype. Humans. Interleukin 1 Receptor Antagonist Protein / genetics. Interleukin-10 / genetics. Interleukin-6 / genetics. Male. Middle Aged. Polymerase Chain Reaction. Prognosis. Tumor Necrosis Factor-alpha / genetics

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21057561.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Egypt
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / Interleukin 1 Receptor Antagonist Protein; 0 / Interleukin-6; 0 / Tumor Necrosis Factor-alpha; 130068-27-8 / Interleukin-10; 9007-49-2 / DNA
  •  go-up   go-down


56. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: In March 1996, a 37 year-old male underwent surgical resection for a left occipital intraventricular benign meningioma (WHO I).
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • Workup studies failed to reveal any primary tumor.
  • In May 2004 the patient was admitted to our department and a new transpedicular biopsy confirmed the diagnosis.
  • Definite pathology: benign meningioma (WHO I).
  • DISCUSSION: Distant metastases from intracranial meningiomas are rare entities, arising from benign lesions in, at least, 60% of cases.
  • Enam et al proposed a specific pathological score to differentiate benign, atypic and malignant meningiomas.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.
  • Hematogenous (especially venous; Batson's perivertebral plexus), linfatic and cerebrospinal fluid are the main routes involved in the spreading of the tumor.
  • [MeSH-major] Meningioma / pathology. Orthopedic Procedures / methods. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery. Thoracic Vertebrae
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Review Literature as Topic

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


57. Glen A, Gan CS, Hamdy FC, Eaton CL, Cross SS, Catto JW, Wright PC, Rehman I: iTRAQ-facilitated proteomic analysis of human prostate cancer cells identifies proteins associated with progression. J Proteome Res; 2008 Mar;7(3):897-907
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differential expression of brain creatine kinase (CKBB), soluble catechol-O-methyltransferase (S-COMT), tumor rejection antigen (gp96), and glucose regulated protein, 78 kDa (grp78), was confirmed by Western blotting or independent 2D-PAGE analysis.
  • The clinical relevance of gp96 was assessed by immunohistochemistry using prostate tissues from benign ( n = 95), malignant ( n = 66), and metastatic cases ( n = 3).
  • Benign epithelium showed absent/weak gp96 expression in the basal cells, in contrast to the moderate/strong expression seen in malignant epithelium.
  • Furthermore, there was a statistically significant difference in the intensity of gp96 expression between benign and malignant cases ( p < 0.0005, Mann-Whitney U).
  • [MeSH-major] Neoplasm Proteins / metabolism. Prostatic Neoplasms / metabolism. Proteomics
  • [MeSH-minor] Cell Line, Tumor. Chromatography, Liquid. Disease Progression. Electrophoresis, Gel, Two-Dimensional. Humans. Immunohistochemistry. Male. Reproducibility of Results. Spectrometry, Mass, Electrospray Ionization / methods


58. Yu AH, Chen L, Li YJ, Zhang GJ, Li KC, Wang YP: Dysembryoplastic neuroepithelial tumors: magnetic resonance imaging and magnetic resonance spectroscopy evaluation. Chin Med J (Engl); 2009 Oct 20;122(20):2433-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysembryoplastic neuroepithelial tumors: magnetic resonance imaging and magnetic resonance spectroscopy evaluation.
  • BACKGROUND: Dysembryoplastic neuroepithelial tumor (DNT) is a rare benign neoplasm of the central nervous system affecting young people.
  • A correct preoperative diagnosis is helpful for planning surgical strategies and improving prognosis.
  • The purpose of this study was to characterize DNTs using magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) and to analyze the value of these two techniques in the diagnosis of DNTs.
  • Tumors were confirmed by surgery.
  • RESULTS: All tumors were supratentorial.
  • The cortex was the main area involved, with nine tumors located in the temporal lobe, three in the frontal lobe, and one on the boundary between the temporal and occipital lobes.
  • Eight tumors had well-demarcated borders.
  • The combination of MRI and MRS techniques were helpful in making a correct presurgical diagnosis.
  • [MeSH-major] Brain Neoplasms / pathology. Magnetic Resonance Imaging / methods. Magnetic Resonance Spectroscopy / methods. Neoplasms, Neuroepithelial / pathology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20079155.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


59. Stavrinou P, Magras I, Stavrinou LC, Zaraboukas T, Polyzoidis KS, Selviaridis P: Primary extracerebral meningeal glioblastoma: clinical and pathological analysis. Cent Eur Neurosurg; 2010 Feb;71(1):46-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Primary meningeal gliomas are uncommon tumors in the subarachnoid space, their primary characteristic being the absence of any obvious connection to the brain parenchyma.
  • Rarely, they are quite malignant and assume a bulky, well circumscribed appearance rendering the differential diagnosis from other CNS neoplasms difficult.
  • At surgery, the outer layer of the dura mater was intact and there was a clear brain-tumor interface without obvious pial disruption.
  • Histological examination showed a biphasic pattern consisting of benign connective tissue intermingled with bundles of what seemed to be a glioblastoma.
  • The tumor was identified as a primary meningeal glioblastoma.
  • This time, the pathological findings of the tumor were those of a typical glioblastoma multiforme.
  • We discuss the origin of the initial neoplasm and also the differential diagnosis that needs to include meningioma, aggressive glioblastoma infiltrating the dura and a recently recognized bimorphic CNS tumor: the desmoplastic glioblastoma.
  • [MeSH-major] Glioblastoma / pathology. Glioblastoma / surgery. Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery
  • [MeSH-minor] Dura Mater / pathology. Glial Fibrillary Acidic Protein / metabolism. Humans. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Glioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart * New York.
  • (PMID = 20175027.001).
  • [ISSN] 1868-4912
  • [Journal-full-title] Central European neurosurgery
  • [ISO-abbreviation] Cent Eur Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen
  •  go-up   go-down


60. Jagannathan J, Kanter AS, Sheehan JP, Jane JA Jr, Laws ER Jr: Benign brain tumors: sellar/parasellar tumors. Neurol Clin; 2007 Nov;25(4):1231-49, xi
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign brain tumors: sellar/parasellar tumors.
  • Neoplasms of the sellar region include pituitary adenomas, craniopharyngiomas, Rathke's cleft cysts, and, less commonly, meningiomas, germinomas, and hamartomas.
  • The diagnosis of sellar lesions involves a multidisciplinary effort; detailed endocrinologic, ophthalmologic, and neurologic tests are critical.
  • The management of pituitary tumors varies.
  • For most tumors, transsphenoidal resection remains the mainstay of treatment.
  • [MeSH-major] Brain Neoplasms / pathology. Pituitary Neoplasms / pathology. Sella Turcica / pathology
  • [MeSH-minor] Acromegaly / diagnosis. Chemotherapy, Adjuvant. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Pituitary ACTH Hypersecretion / diagnosis. Pituitary ACTH Hypersecretion / etiology

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17964033.001).
  • [ISSN] 0733-8619
  • [Journal-full-title] Neurologic clinics
  • [ISO-abbreviation] Neurol Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 69
  •  go-up   go-down


61. Subramanian S, Thayanithy V, West RB, Lee CH, Beck AH, Zhu S, Downs-Kelly E, Montgomery K, Goldblum JR, Hogendoorn PC, Corless CL, Oliveira AM, Dry SM, Nielsen TO, Rubin BP, Fletcher JA, Fletcher CD, van de Rijn M: Genome-wide transcriptome analyses reveal p53 inactivation mediated loss of miR-34a expression in malignant peripheral nerve sheath tumours. J Pathol; 2010 Jan;220(1):58-70
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The malignant transformation of the benign neurofibroma to MPNST is incompletely understood at the molecular level.
  • We have determined the gene expression signature for benign and malignant PNSTs and found that the major trend in malignant transformation from neurofibroma to MPNST consists of the loss of expression of a large number of genes, rather than widespread increase in gene expression.
  • Relatively few genes are expressed at higher levels in MPNSTs and these include genes involved in cell proliferation and genes implicated in tumour metastasis.
  • Subsequent microRNA profiling of benign and malignant PNSTs indicated a relative down-regulation of miR-34a in most MPNSTs compared to neurofibromas.
  • [MeSH-major] Genes, p53. MicroRNAs / metabolism. Nerve Sheath Neoplasms / genetics. RNA, Neoplasm / metabolism
  • [MeSH-minor] Adult. Apoptosis / genetics. Cell Adhesion / genetics. Cell Proliferation. Cluster Analysis. Down-Regulation. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Gene Silencing. Humans. Male. Middle Aged. Neoplasm Proteins / genetics. Neoplasm Proteins / metabolism. Neurofibroma. Oligonucleotide Array Sequence Analysis / methods. Receptor, Epidermal Growth Factor / genetics. Receptor, Epidermal Growth Factor / metabolism. Reverse Transcriptase Polymerase Chain Reaction / methods. Signal Transduction / genetics. Tumor Cells, Cultured. Tumor Suppressor Protein p53 / metabolism


62. Psaras T, Pantazis G, Steger V, Meyermann R, Honegger J, Beschorner R: Benign meningioma developing late lung metastases: case report and review of the literature. Clin Neuropathol; 2009 Nov-Dec;28(6):453-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign meningioma developing late lung metastases: case report and review of the literature.
  • Here we report the case of a 65-year-old female with a histologically benign parietal falcine meningioma who developed multiple lung metastases 15 years after tumor resection.
  • Since it was diagnosed as a benign meningothelial meningioma Grade I WHO, the residual tumor was followed with serial imaging without adjuvant treatment.
  • A repeat brain MRI revealed the known residual meningioma with no signs of interval tumor growth, but did demonstrate occlusion of the sagittal sinus.
  • A review of the literature revealed only 15 well-documented cases of benign meningiomas that metastasized in an interval of up to 12 years after primary tumor resection.
  • This case illustrates that histologically benign meningiomas Grade I WHO with stable disease of the primary tumor have the potential to develop hematogenous metastases even after a long time interval.
  • [MeSH-major] Lung Neoplasms / secondary. Meningeal Neoplasms / pathology. Meningioma / secondary
  • [MeSH-minor] Aged. Female. Humans. Neoplasm, Residual. Time Factors


63. Wu C, Yen YS, Ho DM, Guo W: Primary neurocytoma in the spinal cord. A case report. Neuroradiol J; 2006 Nov 30;19(5):672-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Central neurocytoma is defined as an intraventricular benign brain tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24351271.001).
  • [ISSN] 1971-4009
  • [Journal-full-title] The neuroradiology journal
  • [ISO-abbreviation] Neuroradiol J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Lah TT, Nanni I, Trinkaus M, Metellus P, Dussert C, De Ridder L, Rajcević U, Blejec A, Martin PM: Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. J Neurosurg; 2010 May;112(5):940-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Primary meningioma cultured spheroids were "confronted" with embryonic chick heart spheroids in vitro, and cathepsin B was used as molecular marker to immunolabel the invasive tumor cells.
  • As to the second aim, the possible association of cathepsin B along with selected molecular markers, cathepsin L, and endogenous cysteine protease inhibitors (stefins A and B and cystatin C) with meningioma malignancy was determined using enzyme-linked immunosorbent assays in tumor homogenates.
  • RESULTS: The more invasive tumors, which characteristically overgrew the normal tissue, were identified even within a group of histologically benign meningiomas.
  • More intensive staining of cathepsin B in these tumors was not only found at the tumor front, but also in the invading pseudopodia of a single migrating tumor cells.
  • In the clinical samples of meningioma, the levels of cathepsins B and L, stefin B, and cystatin C were highest in the tumors of higher histological grades, whereas stefin A and progesterone receptor were the only markers that were significantly increased and decreased, respectively, in WHO Grade III lesions.
  • As expected, WHO grade, age, and Simpson grade (complete tumor resection) were prognostic, with Simpson grade only relevant in the short term (up to 90 months) but not in longer-term follow-up.
  • Of note, the known tumor invasiveness marker cathepsin B, measured in whole-tumor homogenates, was not prognostic, in contrast to its endogenous inhibitor stefin B, which was highly significant and the only independent prognostic factor to predict meningioma relapse in multivariate analysis and reported herein for the first time.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Cysteine Proteinase Inhibitors / pharmacology. Cysteine Proteinase Inhibitors / therapeutic use. Lysosomes / drug effects. Meningioma / drug therapy. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cathepsin B / genetics. Cystatin A / genetics. Cystatin B / genetics. Female. Gene Silencing. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neurosurgical Procedures. World Health Organization. Young Adult


65. Kousar A, Hosein MM, Ahmed Z, Minhas K: Rapid sarcomatous transformation of an ameloblastic fibroma of the mandible: case report and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Sep;108(3):e80-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ameloblastic fibrosarcoma (AFS) is a rare malignant odontogenic tumour regarded as the malignant counterpart of ameloblastic fibroma.
  • It is characterized by a benign epithelial component within a malignant fibrous stroma.
  • AFS is a locally aggressive neoplasm with extremely low potential for metastasis.
  • Initially histopathologically diagnosed as a benign lesion, it rapidly recurred with apparent transformation into a high-grade sarcoma over a period of 6 months.
  • [MeSH-major] Cell Transformation, Neoplastic / pathology. Mandibular Neoplasms / pathology. Odontogenic Tumors / pathology. Sarcoma / pathology
  • [MeSH-minor] Brain Neoplasms / secondary. Fatal Outcome. Female. Follow-Up Studies. Humans. Lung Neoplasms / secondary. Masseter Muscle / pathology. Muscle Neoplasms / pathology. Neoplasm Invasiveness. Neoplasm Recurrence, Local / pathology. Radiography, Panoramic. Skull Neoplasms / pathology. Sphenoid Bone / pathology. Tomography, X-Ray Computed. Young Adult

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716496.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 21
  •  go-up   go-down


66. Javahery RJ, Davidson L, Fangusaro J, Finlay JL, Gonzalez-Gomez I, McComb JG: Aggressive variant of a papillary glioneuronal tumor. Report of 2 cases. J Neurosurg Pediatr; 2009 Jan;3(1):46-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive variant of a papillary glioneuronal tumor. Report of 2 cases.
  • Papillary glioneuronal tumors are a newly recognized type of brain neoplasm characterized by prominent pseudopapillary structures and glioneuronal elements.
  • All prior cases have shown that these tumors have an indolent course.
  • The authors present 2 patients with an aggressive variant of the tumor.
  • The first patient had dissemination of her tumor and the second had local spreading.
  • Therefore, the authors conclude that papillary glioneuronal tumors do not always behave in a strictly benign fashion.
  • [MeSH-major] Brain Neoplasms / surgery. Carcinoma, Papillary / surgery. Cerebral Cortex / surgery. Frontal Lobe / surgery. Ganglioglioma / surgery. Neoplasm Recurrence, Local / surgery. Neoplasms, Complex and Mixed / surgery. Neoplasms, Multiple Primary / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19119904.001).
  • [ISSN] 1933-0707
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Vimentin
  •  go-up   go-down


67. Ray WZ, Blackburn SL, Casavilca-Zambrano S, Barrionuevo C, Orrego JE, Heinicke H, Dowling JL, Perry A: Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: a report of 5 cases and review of the literature. J Neurooncol; 2009 Sep;94(2):283-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: a report of 5 cases and review of the literature.
  • Dysembryoplastic neuroepithelial tumors (DNETs) have traditionally been viewed as benign "quasihamartomatous" tumors widely considered curable with surgery alone.
  • Although the radiology was often alarming (e.g., new ring enhancing mass), the pathology remained benign in most cases.
  • These findings suggest that these patients may need closer follow-up than initially suggested, lending further support to the notion that this tumor behaves more like a benign neoplasm, rather than a dysplastic or hamartomatous lesion.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Neuroepithelial / pathology


68. Takei H, Adesina AM, Powell SZ: Solitary subependymal giant cell astrocytoma incidentally found at autopsy in an elderly woman without tuberous sclerosis complex. Neuropathology; 2009 Apr;29(2):181-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subependymal giant cell astrocytoma (SEGA) is a benign, slowly growing tumor typically occurring in the setting of tuberous sclerosis complex (TSC).
  • Postmortem examination of the brain revealed a single 2.1 x 1.0 x 0.8 cm intraventricular nodule in the lateral ventricle.
  • Histologically, it was composed of interlacing bundles of spindle-shaped tumor cells with thin delicate processes admixed with relatively large pleomorphic cells with abundant glassy eosinophilic cytoplasm, as seen in a SEGA.
  • Immunohistochemically, GFAP, S-100 protein, and neuron specific enolase were positive, and synaptophysin labeled a few tumor cells.
  • Also noted were rare isolated MM cells within the tumor (i.e., tumor-to-tumor metastasis).
  • The histopathological differential diagnosis was limited and included giant cell ependymoma and, much less likely, giant cell glioblastoma and pleomorphic xanthoastrocytoma.
  • Tumor metastasis to an occult SEGA is extremely rare.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology
  • [MeSH-minor] Aged. Autopsy. Brain / pathology. Brain / physiopathology. Diagnosis, Differential. Female. Glial Fibrillary Acidic Protein / metabolism. Humans. Immunohistochemistry. Melanoma / pathology. Melanoma / physiopathology. Melanoma / secondary. Neoplasm Metastasis. Phosphopyruvate Hydratase / metabolism. S100 Proteins / metabolism

  • Genetic Alliance. consumer health - Subependymal giant cell astrocytoma.
  • Genetic Alliance. consumer health - Tuberous sclerosis.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18673443.001).
  • [ISSN] 1440-1789
  • [Journal-full-title] Neuropathology : official journal of the Japanese Society of Neuropathology
  • [ISO-abbreviation] Neuropathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / S100 Proteins; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


69. Kano H, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD: Stereotactic radiosurgery for pilocytic astrocytomas part 1: outcomes in adult patients. J Neurooncol; 2009 Nov;95(2):211-218
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Localized solid tumor progression was seen in two patients.
  • Cyst progression was noted in three of nine patients with cystic tumors and mixed solid and cyst progression was noted in two with cystic tumors.
  • The progression free survival after SRS (including tumor growth and cyst enlargement) for the entire series was 83.9%, 31.5% and 31.5% at 1, 3 and 5 years, respectively.
  • Despite their purported benign nature, pilocytic astrocytomas in adult patients often do not behave benignly.
  • Unresectable pilocytic astrocytomas that are located in critical or deep areas of the brain require additional management approaches.
  • Delayed cyst progression contributes to late loss of tumor control.
  • [MeSH-major] Astrocytoma / surgery. Brain Neoplasms / surgery. Neoplasm Recurrence, Local / surgery. Radiosurgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2002 Jul;97(1):56-64 [12134933.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1335-42 [8339223.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):971-3 [2323983.001]
  • [Cites] J Neurosurg. 1973 Dec;39(6):777-9 [4759666.001]
  • [Cites] J Neurooncol. 2006 Jan;76(1):55-8 [16132503.001]
  • [Cites] Br J Neurosurg. 2004 Dec;18(6):613-6 [15799194.001]
  • [Cites] Br J Ophthalmol. 1969 Dec;53(12):793-8 [5386369.001]
  • [Cites] J Neurosurg. 2003 Jun;98(6):1170-4 [12816259.001]
  • [Cites] Cancer. 1985 Oct 1;56(7 Suppl):1841-6 [4027923.001]
  • [Cites] J Neurosurg. 2002 Dec;97(5 Suppl):677-80 [12507119.001]
  • [Cites] Cancer. 2007 Dec 15;110(12 ):2799-808 [17973253.001]
  • [Cites] Pediatr Neurosurg. 1996 Sep;25(3):109-15 [9144708.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):68-78 [8121571.001]
  • [Cites] Acta Neurochir (Wien). 1986;81(1-2):11-26 [3728086.001]
  • [Cites] Neurosurgery. 1990 Feb;26(2):242-6; discussion 246-7 [2308672.001]
  • [Cites] Neurosurg Rev. 1990;13(4):315-20 [2280843.001]
  • [Cites] Arch Neurol. 1968 Jan;18(1):14-9 [5634368.001]
  • [Cites] J Neurosurg. 1985 Sep;63(3):382-6 [4020465.001]
  • [Cites] Acta Neurochir (Wien). 1986;81(3-4):90-3 [3751698.001]
  • [Cites] Arch Neurol. 1971 Feb;24(2):125-35 [5540377.001]
  • [Cites] Radiology. 1993 Oct;189(1):221-5 [8372197.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):161-8 [17347491.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):964-71 [8134009.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1153-60 [15001258.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):815-8 [2323970.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):856-69 [8334640.001]
  • [Cites] Pediatr Neurosurg. 1990-1991;16(4-5):219-21 [2135190.001]
  • [Cites] Childs Brain. 1983;10(2):79-91 [6839871.001]
  • (PMID = 19468691.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


70. Majores M, von Lehe M, Fassunke J, Schramm J, Becker AJ, Simon M: Tumor recurrence and malignant progression of gangliogliomas. Cancer; 2008 Dec 15;113(12):3355-63
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor recurrence and malignant progression of gangliogliomas.
  • BACKGROUND: Most gangliogliomas (GGs) are benign tumors, but tumor recurrence and malignant progression are observed in some patients.
  • METHODS: The authors analyzed their experience with 4 recurrent/progressive GGs (World Health Organization [WHO] grade I), 21 tumors with atypical features (WHO grade II), and 5 tumors with anaplastic histologic features (WHO grade III).
  • RESULTS: The 5-year survival rates were only 79% for patients who had tumors with atypical features and 53% for patients who had WHO grade III tumors.
  • Secondary glioblastomas were diagnosed in 5 of 11 patients (45%) who underwent surgery for tumor recurrence.
  • Patients who had extratemporal tumors had a significantly shorter PFS (P = .01) but not OS.
  • Neuropathologic examination revealed the presence of a gemistocytic cell component (PFS, P = .025), a lack of protein droplets (OS, P = .04; PFS, P = .05), and focal tumor cell-associated CD34 immunolabeling (OS, P = .03) as significant predictors of an adverse clinical course.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Disease Progression. Epilepsy / epidemiology. Female. Humans. Infant. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Analysis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18988291.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Nakamura M, Ishii K, Watanabe K, Tsuji T, Matsumoto M, Toyama Y, Chiba K: Long-term surgical outcomes for myxopapillary ependymomas of the cauda equina. Spine (Phila Pa 1976); 2009 Oct 1;34(21):E756-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because of the rarity of this tumor, there is no consensus on its optimal treatment options and prognosis.
  • The effects of surgical margins at surgery and postoperative radiotherapy on tumor recurrence and prognosis were investigated.
  • RESULTS: In 15 patients, total resection achieved (6 cases of en bloc resection without postoperative radiation, and in 9 cases piecemeal resection) was followed by whole brain and spinal cord radiation or local irradiation.
  • Fourteen of these patients survived without tumor recurrence.
  • In 1 case of total resection without radiotherapy, the tumor capsule was violated intraoperatively and local recurrence occurred 2 years after surgery.
  • In 4 patients, the tumors were removed subtotally.
  • Of these, 2 patients who received radiation (24 Gy) only to the whole brain and spinal cord developed recurrence, and 2 who received whole brain and spinal cord radiation (24 Gy) supplemented with local radiation (46 Gy) developed no recurrence.
  • Although this tumor is histologically benign, CSF dissemination can occur once tumor capsule is violated, before or during surgery.
  • Therefore, early diagnosis is essential, and a therapeutic strategy including radiotherapy, on the assumption that this tumor is malignant, should be established.
  • [MeSH-major] Cauda Equina. Ependymoma / surgery. Neurosurgical Procedures. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Incidence. Longitudinal Studies. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Prognosis. Radiotherapy, Adjuvant / methods. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19934795.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


72. Sasikala M, Kumaravel N: A wavelet-based optimal texture feature set for classification of brain tumours. J Med Eng Technol; 2008 May-Jun;32(3):198-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A wavelet-based optimal texture feature set for classification of brain tumours.
  • In this work, the classification of brain tumours in magnetic resonance images is studied by using optimal texture features.
  • These features are used to classify three sets of brain images - normal brain, benign tumour and malignant tumour.
  • Each selected brain region of interest is characterized with both its energy and texture features extracted from the selected high frequency subband.
  • [MeSH-major] Algorithms. Artificial Intelligence. Brain Neoplasms / diagnosis. Image Interpretation, Computer-Assisted / methods. Magnetic Resonance Imaging / methods. Pattern Recognition, Automated / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18432467.001).
  • [ISSN] 0309-1902
  • [Journal-full-title] Journal of medical engineering & technology
  • [ISO-abbreviation] J Med Eng Technol
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


73. Caffo M, Caruso G, Galatioto S, Meli F, Cacciola F, Germanò A, Alafaci C, Tomasello F: Immunohistochemical study of the extracellular matrix proteins laminin, fibronectin and type IV collagen in secretory meningiomas. J Clin Neurosci; 2008 Jul;15(7):806-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Secretory meningiomas are rare histological meningioma subtypes that have benign behavior, are highly vascularized and are frequently accompanied by massive peritumoral edema.
  • Meningiomas increase in size through increased production of extracellular matrix; furthermore, the proliferation of cells typically associated with neoplasia requires considerable interaction with the extracellular matrix.
  • [MeSH-major] Brain Neoplasms / metabolism. Extracellular Matrix / metabolism. Extracellular Matrix Proteins / metabolism. Meningioma / metabolism. Neoplasm Invasiveness / physiopathology
  • [MeSH-minor] Aged. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Cell Proliferation. Collagen Type IV / metabolism. Fibronectins / metabolism. Humans. Immunohistochemistry. Laminin / metabolism. Middle Aged. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18474427.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Collagen Type IV; 0 / Extracellular Matrix Proteins; 0 / Fibronectins; 0 / Laminin
  •  go-up   go-down


74. Temprano T, Fernández-de León R, Rial JC, Fernández JM, Mateos V: [Cystic bulbar hemangioblastoma]. Rev Neurol; 2008 Aug 1-15;47(3):134-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Hemangioblastoma quístico de bulbo raquídeo.
  • INTRODUCTION: Hemangioblastomas are neoplasm of vascular type having benign characteristics.
  • They represent between 2-3% of brain tumors and 7-12% of neoformative processes in the posterior fossa.
  • Brain tumor was diagnosed by neuroimage techniques.
  • The histological study confirmed the hemangioblastoma diagnosis.
  • The bulbar localization is infrequent (which represents less percentage than 5% of cerebral hemangioblastomas) likewise the clinical manifestation though hiccups.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Hemangioblastoma / diagnosis

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18654967.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


75. Składzień J, Oleś K, Moskała M, Strek P, Urbanik A, Stachura J, Zagólski O: [Own experience in treatment of patients with advanced tumours of the paranasal sinuses and the orbit, penetrating to the anterior and medial cranial fossa--preliminary report]. Otolaryngol Pol; 2007;61(4):416-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Vital structures, such as the dura, brain, and blood vessels, can be protected or resected and reconstructed safely.
  • An en bloc excision of the tumour can be accomplished.
  • RESULTS: Lesions were malignant in 7 patients and benign in the remaining 33.
  • Craniofacial resection is the only surgical approach with acceptable rate of complications in selected patients with tumour comprising the anterior and medial cranial base, nasal cavity, paranasal sinuses, nasopharynx and orbits.
  • [MeSH-major] Cranial Fossa, Anterior / surgery. Cranial Fossa, Middle / surgery. Orbital Neoplasms / surgery. Paranasal Sinus Neoplasms / surgery. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18260224.001).
  • [ISSN] 0030-6657
  • [Journal-full-title] Otolaryngologia polska = The Polish otolaryngology
  • [ISO-abbreviation] Otolaryngol Pol
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


76. Rogers L, Gilbert M, Vogelbaum MA: Intracranial meningiomas of atypical (WHO grade II) histology. J Neurooncol; 2010 Sep;99(3):393-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical (WHO grade II) meningiomas occupy an intermediate risk group between benign (WHO grade I) and anaplastic (WHO grade III) meningiomas.
  • We will discuss the definition, diagnosis, and treatment of patients with atypical meningioma; review the current phase II cooperative trials; and draw attention to some questions timely for pre-clinical and clinical research.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Humans. Neoplasm Staging. Prognosis. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neurosurgery. 2009 Jan;64(1):56-60; discussion 60 [19145156.001]
  • [Cites] Radiology. 1987 Aug;164(2):521-6 [3496626.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] Clin Nucl Med. 2005 Nov;30(11):717-20 [16237292.001]
  • [Cites] J Neurooncol. 2007 Aug;84(1):41-7 [17361335.001]
  • [Cites] Neurol Res. 1999 Oct;21(7):640-4 [10555183.001]
  • [Cites] Acta Neurochir (Wien). 1995;135(3-4):171-8 [8748810.001]
  • [Cites] J Neurosurg. 2000 May;92(5):766-70 [10794289.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] Brain Pathol. 2003 Jul;13(3):386-408 [12946028.001]
  • [Cites] Int J Cancer. 2003 May 10;104(6):728-34 [12640680.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Eur J Radiol. 2006 Oct;60(1):48-55 [16844335.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):384-90 [10470811.001]
  • [Cites] Neurol Res. 2007 Jan;29(1):43-6 [17427274.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Jun;29(6):1147-52 [18356472.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Clin Radiol. 2007 Feb;62(2):109-19 [17207692.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jan 1;49(1):99-105 [11163502.001]
  • [Cites] Neuroradiology. 1990;32(6):467-73 [2287373.001]
  • [Cites] Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9 [15771707.001]
  • [Cites] Neurosurgery. 1993 Sep;33(3):394-9; discussion 399 [8413869.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Jul 1;68(3):858-63 [17379447.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):817-22 [8598358.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Feb;17 (2):345-53 [8938309.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(9):921-32 [10526073.001]
  • [Cites] Neurosurgery. 2009 Feb;64(2 Suppl):A7-13 [19165077.001]
  • [Cites] Clin Nucl Med. 2009 Jan;34(1):7-10 [19092373.001]
  • [Cites] J Clin Neurosci. 2003 Sep;10(5):589-93 [12948465.001]
  • [Cites] Neuroradiology. 2006 Aug;48(8):513-20 [16786348.001]
  • [Cites] J Neurosurg. 1999 Dec;91(6):928-34 [10584837.001]
  • [Cites] Neurosurgery. 2005 Dec;57(6):1088-95; discussion 1088-95 [16331155.001]
  • [Cites] Cancer. 2002 Mar 1;94(5):1538-47 [11920512.001]
  • [Cites] Osaka City Med J. 1997 Dec;43(2):209-23 [9540343.001]
  • [Cites] AJNR Am J Neuroradiol. 2008 Oct;29(9):1630-5 [18583409.001]
  • [Cites] Chin Med J (Engl). 2008 Dec 5;121(23):2415-9 [19102960.001]
  • [Cites] Neurosurgery. 2003 Jul;53(1):62-70; discussion 70-1 [12823874.001]
  • [Cites] J Neurosurg. 2005 Jan;102 Suppl:283-6 [15662826.001]
  • [Cites] Clin Imaging. 2008 Jan-Feb;32(1):22-7 [18164390.001]
  • [Cites] Ann N Y Acad Sci. 1982;381:6-16 [6953802.001]
  • [Cites] Neurosurgery. 1993 Dec;33(6):955-63 [8134008.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Oct;36(10 ):1574-82 [19377904.001]
  • [Cites] Strahlenther Onkol. 1998 Dec;174(12):624-8 [9879349.001]
  • [Cites] Surg Neurol. 2004 Feb;61(2):171-3 [14751635.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):293-6; discussion 296-7 [16953450.001]
  • [Cites] Am J Clin Oncol. 2005 Feb;28(1):70-4 [15685038.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Neurosurgery. 2010 Apr;66(4):661-8; discussion 668-9 [20305491.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • [Cites] Neurosurgery. 2008 May;62(5 Suppl):A19-27; discussion A27-8 [18580776.001]
  • [Cites] Eur Radiol. 2003 Mar;13(3):582-91 [12594562.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] J Neurooncol. 1998 Aug;39(1):65-70 [9760071.001]
  • [Cites] Curr Opin Neurol. 2010 Dec;23(6):563-70 [20885321.001]
  • [Cites] Radiologia. 2009 Jul-Aug;51(4):411-9 [19552929.001]
  • [Cites] J Neurosurg. 1996 Jun;84(6):946-50 [8847588.001]
  • [Cites] Acta Neurochir Suppl. 1996;65:108-11 [8738510.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] J Nucl Med. 1997 Jan;38(1):26-30 [8998144.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] AJNR Am J Neuroradiol. 2001 Jan;22(1):65-72 [11158890.001]
  • [Cites] Neurosurg Focus. 2008;24(5):E3 [18447742.001]
  • [Cites] Radiology. 2005 Jun;235(3):985-91 [15833979.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E4 [17961041.001]
  • [Cites] J Neuroradiol. 1992;19(1):49-62 [1564530.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Oct 1;75(2):399-406 [19203844.001]
  • (PMID = 20740303.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


77. Walker RA, Wadman MC: Headache in the elderly. Clin Geriatr Med; 2007 May;23(2):291-305, v-vi
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Particular emphasis should be placed on excluding subarachnoid hemorrhage, subdural hematoma, giant cell arteritis, intracranial neoplasm, cerebrovascular accident, acute-angle-closure glaucoma, and infectious etiologies such as meningitis and encephalitis.
  • Once life-threatening disorders are excluded, the geriatrician can focus on more benign etiologies such as migraine, tension headache, and medication withdrawal.
  • This article discusses headaches that require emergent treatment and then describes more benign etiologies of headaches.
  • [MeSH-major] Brain Diseases / complications. Headache / etiology
  • [MeSH-minor] Aged. Carbon Monoxide Poisoning / complications. Carbon Monoxide Poisoning / diagnosis. Glaucoma, Angle-Closure / complications. Glaucoma, Angle-Closure / diagnosis. Headache Disorders, Primary / diagnosis. Humans. Meningitis / complications. Meningitis / diagnosis

  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • MedlinePlus Health Information. consumer health - Headache.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462518.001).
  • [ISSN] 0749-0690
  • [Journal-full-title] Clinics in geriatric medicine
  • [ISO-abbreviation] Clin. Geriatr. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 68
  •  go-up   go-down


78. Ek S, Dictor M, Jerkeman M, Jirström K, Borrebaeck CA: Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood; 2008 Jan 15;111(2):800-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we show that the transcription factor Sox11 is specifically expressed in the nucleus of MCL compared with other lymphomas and benign lymphoid tissue.
  • Sox11 mRNA is increased in gliomas compared with healthy brain tissue, suggesting a role in malignant transformation and/or cell survival.
  • Our novel finding of specific overexpression of Sox11 mRNA and nuclear protein in both cyclin D1-positive and - negative MCL may be useful for the diagnosis of MCL as a complement to cyclin D1 and also suggests a functional role for Sox11 in MCL.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Cell Nucleus / metabolism. Cell Transformation, Neoplastic / metabolism. Gene Expression Regulation, Leukemic. High Mobility Group Proteins / biosynthesis. Lymphoma, Mantle-Cell / metabolism. Neoplasm Proteins / biosynthesis
  • [MeSH-minor] Antigens, CD20 / genetics. Antigens, CD20 / metabolism. Antigens, CD5 / genetics. Antigens, CD5 / metabolism. B-Lymphocytes / pathology. Brain / metabolism. Brain / pathology. Brain Neoplasms / genetics. Brain Neoplasms / metabolism. Brain Neoplasms / pathology. Central Nervous System / embryology. Central Nervous System / metabolism. Central Nervous System / pathology. Cyclin D. Cyclins / genetics. Cyclins / metabolism. Embryo, Mammalian / metabolism. Embryo, Mammalian / pathology. Gene Expression Profiling. Gene Expression Regulation, Developmental. Glioma / genetics. Glioma / metabolism. Glioma / pathology. Humans. Lymphopoiesis / genetics. Oligonucleotide Array Sequence Analysis. Organ Specificity. SOXC Transcription Factors. Sequence Homology, Amino Acid. Trans-Activators / biosynthesis. Trans-Activators / genetics


79. Saito R, Kumabe T, Watanabe M, Jokura H, Shibuya M, Nakazato Y, Tominaga T: Low-grade fibromyxoid sarcoma of intracranial origin. J Neurosurg; 2008 Apr;108(4):798-802
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The low-grade fibromyxoid sarcoma is a rare sarcoma of the deep soft tissue that is characterized as an indolent but metastasizing soft-tissue neoplasm with a deceptively benign histological appearance.
  • A high rate of local recurrence and eventual metastasis has been demonstrated for this tumor in deep soft tissue.
  • The tumor is still under control without any evidence of extracranial metastasis.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / therapy. Sarcoma / diagnosis. Sarcoma / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Neoplasm Recurrence, Local / prevention & control. Radiosurgery. Radiotherapy, Adjuvant. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18377261.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Guan M, Chen Y: Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score. J Clin Pathol; 2005 Nov;58(11):1175-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant expression of DeltaNp73 in benign and malignant tumours of the prostate: correlation with Gleason score.
  • N-terminal truncated isoforms of p73 (DeltaNp73) act as dominant-negative inhibitors of wild-type p53 and TAp73 and result in tumour growth in nude mice.
  • AIMS: To detect DeltaNp73 expression in 24 benign prostatic hyperplasia samples, 33 prostate carcinomas, and five normal samples and to evaluate the relation between DeltaNp73, TAp73 concentrations, and the clinicopathological characteristics of patients with prostate cancer.
  • RESULTS: A significant increase of DeltaNp73 was seen in 20 of 33 carcinomas and 17 of 24 benign prostate hyperplasia tissues, but in none of the normal samples.
  • [MeSH-major] Biomarkers, Tumor / metabolism. DNA-Binding Proteins / metabolism. Nuclear Proteins / metabolism. Prostatic Neoplasms / metabolism. Tumor Suppressor Proteins / metabolism
  • [MeSH-minor] Aged. Blotting, Western. Disease Progression. Humans. Male. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction / methods. Prostate / metabolism. Prostatic Hyperplasia / metabolism. Prostatic Hyperplasia / pathology. Reverse Transcriptase Polymerase Chain Reaction / methods. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cell Death Differ. 2001 Dec;8(12):1213-23 [11753569.001]
  • [Cites] Cancer Res. 1993 Jul 15;53(14):3369-73 [8324747.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):165-70 [11801554.001]
  • [Cites] Trends Genet. 2002 Feb;18(2):90-5 [11818141.001]
  • [Cites] Cancer Res. 2002 Feb 1;62(3):636-41 [11830511.001]
  • [Cites] Cell Death Differ. 2002 Mar;9(3):343-5 [11859417.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3598-602 [12097259.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4715-27 [12101410.001]
  • [Cites] J Exp Med. 2002 Sep 16;196(6):765-80 [12235210.001]
  • [Cites] Acta Oncol. 2002;41(6):550-5 [12546528.001]
  • [Cites] Prostate Cancer Prostatic Dis. 2003;6(2):174-81 [12806379.001]
  • [Cites] Jpn J Clin Oncol. 2003 May;33(5):215-20 [12865464.001]
  • [Cites] Int J Cancer. 2004 Jan 1;108(1):162-6 [14618632.001]
  • [Cites] Oncol Rep. 2004 Jun;11(6):1337-41 [15138575.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6905-11 [15501968.001]
  • [Cites] Cell. 1997 Aug 22;90(4):809-19 [9288759.001]
  • [Cites] Nature. 1997 Sep 11;389(6647):191-4 [9296498.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2076-7 [9605745.001]
  • [Cites] J Natl Cancer Inst. 1999 Jul 7;91(13):1154-8 [10393724.001]
  • [Cites] Nat Genet. 2000 Dec;26(4):464-9 [11101847.001]
  • [Cites] Clin Cancer Res. 2001 Jan;7(1):81-8 [11205922.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):296-305 [11414472.001]
  • [Cites] Ann Oncol. 2001 Jul;12(7):981-6 [11521806.001]
  • [Cites] J Natl Cancer Inst. 1992 Jun 3;84(11):883-7 [1350643.001]
  • [Cites] Chin Med J (Engl). 2000 Apr;113(4):299-302 [11775222.001]
  • (PMID = 16254107.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Tumor Suppressor Proteins
  • [Other-IDs] NLM/ PMC1770779
  •  go-up   go-down


81. Kung B, Aftab S, Wood M, Rosen D: Malignant melanoma metastatic to the thyroid gland: a case report and review of the literature. Ear Nose Throat J; 2009 Jan;88(1):E7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soon thereafter, the patient began experiencing seizures, and on magnetic resonance imaging, he was found to have metastatic disease to the brain.
  • Patients who present with a thyroid nodule and who have a history of malignancy present a diagnostic dilemma: Is the nodule benign, a new primary, or a distant metastasis?
  • [MeSH-major] Melanoma / secondary. Neoplasm Invasiveness / pathology. Thyroid Neoplasms / secondary. Thyroid Nodule / pathology
  • [MeSH-minor] Aged. Biopsy, Fine-Needle. Follow-Up Studies. Humans. Immunohistochemistry. Lymph Nodes / pathology. Male. Neck Dissection. Neoplasm Staging. Risk Assessment. Thyroidectomy / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19172560.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 14
  •  go-up   go-down


82. Simon SL, Moonis G, Judkins AR, Scobie J, Burnett MG, Riina HA, Judy KD: Intracranial capillary hemangioma: case report and review of the literature. Surg Neurol; 2005 Aug;64(2):154-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Capillary hemangiomas are benign vascular lesions that commonly present at birth or in early infancy on the face, scalp, back, or chest.
  • The patient underwent a resection of her tumor, which was diagnosed as a capillary hemangioma by histopathologic examination.
  • The patient required 2 further resections after the lesion exhibited a rapid regrowth from residual tumor in the left transverse sinus.
  • [MeSH-major] Brain Neoplasms / surgery. Hemangioma, Capillary / surgery. Neoplasm Recurrence, Local / surgery. Pregnancy Complications, Neoplastic / surgery


83. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD: Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol; 2009 Dec;11(6):853-60
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08).
  • The North American Brain Tumor Consortium conducted a phase II study to evaluate the therapeutic potential of imatinib mesylate (Gleevec), a PDGFR inhibitor, in patients with recurrent meningiomas.
  • Patients were stratified into benign (WHO grade I) meningiomas or atypical (WHO grade II) and malignant (WHO grade III) meningiomas.
  • Twenty-three heavily pretreated patients were enrolled into the study (13 benign, 5 atypical, and 5 malignant meningiomas), of whom 22 were eligible.
  • For benign meningiomas, median PFS was 3 months (range, 1.1-34 months); 6M-PFS was 45%.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 2001;18(1):1-5 [11517968.001]
  • [Cites] Blood. 2008 Apr 15;111(8):4022-8 [18256322.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1031-7 [11287972.001]
  • [Cites] N Engl J Med. 2001 Apr 5;344(14):1038-42 [11287973.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:49-53 [11386826.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):39-44 [12798163.001]
  • [Cites] Neurology. 2004 Apr 13;62(7):1210-2 [15079029.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] J Clin Oncol. 1990 Jul;8(7):1277-80 [2358840.001]
  • [Cites] Int J Cancer. 1990 Jul 15;46(1):16-21 [2163990.001]
  • [Cites] J Clin Invest. 1990 Jul;86(1):131-40 [2164040.001]
  • [Cites] Int J Cancer. 1990 Nov 15;46(5):772-8 [1699901.001]
  • [Cites] J Biol Chem. 1991 Sep 5;266(25):16755-63 [1653246.001]
  • [Cites] Cancer Res. 1992 Jun 1;52(11):3213-9 [1317261.001]
  • [Cites] J Neurooncol. 1992 Jun;13(2):157-64 [1432033.001]
  • [Cites] J Neurooncol. 1993 Jan;15(1):75-7 [8455065.001]
  • [Cites] J Neurosurg. 1994 Sep;81(3):388-93 [8057146.001]
  • [Cites] Int J Cancer. 1995 Jan 17;60(2):168-73 [7829210.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):100-4 [8548747.001]
  • [Cites] J Neurosurg. 1996 May;84(5):852-8; discussion 858-9 [8622161.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):197-205 [8858525.001]
  • [Cites] J Neurooncol. 1996 Sep;29(3):261-7 [8858532.001]
  • [Cites] Neurosurgery. 1997 Feb;40(2):271-5 [9007858.001]
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] J Neurooncol. 1997 Dec;35(3):289-301 [9440026.001]
  • [Cites] J Neurosurg. 1998 May;88(5):938-9 [9576275.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] Br J Neurosurg. 2004 Oct;18(5):495-9 [15799152.001]
  • [Cites] Clin Pharmacokinet. 2005;44(9):879-94 [16122278.001]
  • [Cites] Ann Oncol. 2005 Oct;16(10):1702-8 [16033874.001]
  • [Cites] J Clin Oncol. 2005 Dec 20;23(36):9359-68 [16361636.001]
  • [Cites] J Neurooncol. 2006 Jul;78(3):271-6 [16628476.001]
  • [Cites] Br J Clin Pharmacol. 2006 Jul;62(1):97-112 [16842382.001]
  • [Cites] Clin Cancer Res. 2006 Aug 15;12(16):4899-907 [16914578.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):145-60 [17293590.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3496-9 [17192396.001]
  • [Cites] Neurosurg Focus. 2007;23(4):E12 [17961036.001]
  • [Cites] PLoS Med. 2008 Jan 29;5(1):e24 [18232729.001]
  • [Cites] Neurosurgery. 2001 Nov;49(5):1029-37; discussion 1037-8 [11846894.001]
  • (PMID = 19293394.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA062407; United States / NCRR NIH HHS / RR / M01 RR000079; United States / NCRR NIH HHS / RR / M01 RR003186; United States / NCRR NIH HHS / RR / M01 RR000056; United States / NCRR NIH HHS / RR / M01 RR000865; United States / NCI NIH HHS / CA / U01 CA062399; United States / NCRR NIH HHS / RR / M01 RR000633; United States / NCI NIH HHS / CA / U01 CA062412; United States / NCI NIH HHS / CA / CA 62399; United States / NCI NIH HHS / CA / CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421-07; United States / NCI NIH HHS / CA / U01 CA062421; United States / NCI NIH HHS / CA / U01 CA105663
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Other-IDs] NLM/ PMC2802405
  •  go-up   go-down


84. Nohara H, Furuya K, Kawahara N, Iijima A, Yako K, Shibahara J, Kirino T: Lymphoplasmacyte-rich meningioma with atypical invasive nature. Neurol Med Chir (Tokyo); 2007 Jan;47(1):32-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was subtotally removed.
  • Histological examination showed the tumor had invaded the normal brain tissue despite its benign grade in the World Health Organization classification.
  • The Ki-67 staining index using MIB-1 monoclonal antibody was relatively high. (18)F-2-fluoro-2-deoxy-D-glucose positron emission tomography revealed high uptake in the tumor.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningioma / pathology. Plasma Cells
  • [MeSH-minor] Adolescent. Humans. Male. Neoplasm Invasiveness

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17245013.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


85. Marton E, Feletti A, Orvieto E, Longatti P: Malignant progression in pleomorphic xanthoastrocytoma: personal experience and review of the literature. J Neurol Sci; 2007 Jan 31;252(2):144-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pleomorphic xanthoastrocytoma (PXA) is a rare primary low-grade astrocytic tumor, recently classified as a neuroglial tumor.
  • It generally occurs in children and young adults and shows benign behaviour (WHO II), although an anaplastic variant and malignant potential have been described.
  • Pleomorphic xanthoastrocytomas with malignant transformation have been reported in three out of eight patients operated on for this type of tumor in our department in the last 15 years.
  • The three patients were two adult women and a child, the primary tumors were located in the cortex of the right temporal lobe, and treatment consisted of complete surgical resection.
  • Two died from tumor progression and one from brain edema after intracerebral haemorrhage.
  • Accordingly, these tumors demand close long-term clinical and radiological follow-up.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Glioblastoma / pathology
  • [MeSH-minor] Adult. Cell Transformation, Neoplastic. Child. Disease Progression. Fatal Outcome. Female. Humans. Magnetic Resonance Imaging. Middle Aged. Neoplasm Recurrence, Local / pathology. Tomography, X-Ray Computed


86. Happle C, Wetzke M, Hermann EJ, Krauss JK, Hartmann H, Lücke T: ['Cases against KiSS': a diagnostic algorithm for children with torticollis]. Klin Padiatr; 2009 Dec;221(7):430-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present two infants with brain tumours who developed torticollis and further neurological findings such as ataxia and reflex differences.
  • In both cases, symptoms caused by the tumour were interpreted as "KiSS-syndrome", and appropriate diagnostics and therapy were delayed for months.
  • Whereas most cases are benign, there is a long list of serious differential diagnoses for torticollis in infants.
  • [MeSH-major] Algorithms. Astrocytoma / diagnosis. Cerebellar Neoplasms / diagnosis. Cervical Vertebrae. Ganglioglioma / diagnosis. Magnetic Resonance Imaging. Neoplasms, Second Primary / diagnosis. Spinal Diseases / diagnosis. Torticollis / etiology
  • [MeSH-minor] Child, Preschool. Diagnostic Errors. Gait Disorders, Neurologic / etiology. Humans. Infant. Male. Microsurgery. Neoplasm, Residual / diagnosis. Neurologic Examination. Postoperative Complications / diagnosis. Reoperation. Syndrome

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Neck Injuries and Disorders.
  • MedlinePlus Health Information. consumer health - Spine Injuries and Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) Georg Thieme Verlag KG Stuttgart New York.
  • (PMID = 20013566.001).
  • [ISSN] 1439-3824
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


87. Korshunov A, Cherekaev V, Bekyashev A, Sycheva R: Recurrent cytogenetic aberrations in histologically benign, invasive meningiomas of the sphenoid region. J Neurooncol; 2007 Jan;81(2):131-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrent cytogenetic aberrations in histologically benign, invasive meningiomas of the sphenoid region.
  • Mean number of aberrations detected per tumor was significantly greater for invasive meningiomas-67.4 compared with 40.5 for non-invasive MSR.
  • Thus, the presence of a complex cytogenetic profile and progression-associated chromosomal aberrations in benign MSR is associated with their increased invasive potential.
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics. Sphenoid Bone / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Tumor Pathol. 2004;21(1):27-34 [15696966.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2653-61 [15805262.001]
  • [Cites] Surg Neurol. 2005 Jul;64(1):37-43; discussion 43 [15993178.001]
  • [Cites] Brain Tumor Pathol. 2003;20(2):59-63 [14756442.001]
  • [Cites] Clin Cancer Res. 2004 Feb 1;10 (3):869-80 [14871962.001]
  • [Cites] Cancer Genet Cytogenet. 2001 Aug;129(1):88-91 [11520574.001]
  • [Cites] Brain Tumor Pathol. 2004;21(3):127-33 [15696974.001]
  • [Cites] Arch Pathol Lab Med. 2002 Sep;126(9):1079-86 [12204057.001]
  • [Cites] Neurosurgery. 2004 Nov;55(5):1163-73 [15509323.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):167-74 [10222437.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):256-65 [15009703.001]
  • [Cites] Brief Funct Genomic Proteomic. 2003 Apr;2(1):37-45 [15239942.001]
  • [Cites] Brain Pathol. 2001 Jul;11(3):296-305 [11414472.001]
  • [Cites] Oncol Rep. 2005 Dec;14(6):1583-8 [16273260.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):63-7 [16157202.001]
  • [Cites] J Neurosurg. 2004 Feb;100(2):303-9 [15098535.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):491-7 [16235682.001]
  • [Cites] J Neurosurg. 2001 Oct;95(4):601-7 [11596954.001]
  • [Cites] Acta Neuropathol. 2006 May;111(5):465-74 [16557391.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Apr 15;110(2):103-10 [10214357.001]
  • [Cites] Neurosurgery. 1999 Apr;44(4):742-6; discussion 746-7 [10201298.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17):3285-95 [12947064.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jul 1;120(1):30-6 [10913674.001]
  • [Cites] Am J Clin Pathol. 2001 Feb;115(2):213-8 [11211609.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] J Pathol. 2004 Jul;203(3):780-8 [15221937.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):145-53 [11958368.001]
  • [Cites] Neurol Res. 2005 Oct;27(7):747-54 [16197812.001]
  • [Cites] J Oral Pathol Med. 2006 Mar;35(3):136-9 [16454808.001]
  • [Cites] Neuro Oncol. 2004 Oct;6(4):281-9 [15494095.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Apr;63(4):275-86 [15099018.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7121-6 [16103061.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):744-51 [15981814.001]
  • (PMID = 16850103.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. de Ipolyi AR, Yang I, Buckley A, Barbaro NM, Cheung SW, Parsa AT: Fluctuating response of a cystic vestibular schwannoma to radiosurgery: case report. Neurosurgery; 2008 May;62(5):E1164-5; discussion E1165
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: A vestibular schwannoma (VS) is a benign tumor of the VIIIth cranial nerve that can often be treated by microsurgery or radiosurgery and demonstrates high tumor control rates.
  • INTERVENTION: After GKS with a 12-Gy dose to the 50% isodose line, the tumor expanded transiently to 3.2 cm and then regressed to 1.0 cm over the next 2 years.
  • After microsurgical tumor excision, the patient's symptoms abated.
  • The mechanisms responsible for radiation-induced cystic tumor expansion have not been thoroughly elucidated.
  • The risk of unpredictable tumor enlargement should be discussed with patients when considering GKS for cystic tumors.
  • [MeSH-major] Neoplasm Recurrence, Local / surgery. Neuroma, Acoustic / pathology. Neuroma, Acoustic / surgery. Radiosurgery
  • [MeSH-minor] Aged. Breast Neoplasms / pathology. Cysts / pathology. Cysts / surgery. Female. Hearing Loss / etiology. Humans. Hyperthyroidism / pathology. Magnetic Resonance Imaging. Microsurgery. Neoplasms, Second Primary / pathology. Neoplasms, Second Primary / surgery

  • Genetic Alliance. consumer health - Schwannoma.
  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580785.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Naumann IC, Cordes SR: Giant basal cell carcinoma of the forehead with extensive intracranial involvement. Ann Otol Rhinol Laryngol; 2007 Sep;116(9):663-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Despite its fairly benign growth pattern, BCC should never be underestimated, and care should be taken not only in the complete primary excision but also in cancer surveillance.
  • [MeSH-major] Brain Neoplasms / pathology. Carcinoma, Basal Cell / pathology. Forehead. Head and Neck Neoplasms / pathology
  • [MeSH-minor] Aged. Biopsy. Diagnosis, Differential. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Neoplasm Invasiveness. Neoplasm Recurrence, Local / diagnostic imaging. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neurosurgical Procedures / methods. Reconstructive Surgical Procedures / methods. Severity of Illness Index. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17926588.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


90. Agaoglu FY, Ayan I, Dizdar Y, Kebudi R, Gorgun O, Darendeliler E: Ependymal tumors in childhood. Pediatr Blood Cancer; 2005 Sep;45(3):298-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ependymal tumors in childhood.
  • BACKGROUND: Ependymal tumors are classified as ependymoma (benign or low grade) versus anaplastic ependymoma (malignant or high grade).
  • Ependymomas represent 5-10% of intracranial neoplasm in children.
  • In this study, demographic data and the treatment results of pediatric patients with ependymal tumors, treated in a single institute, is reported.
  • PATIENTS AND METHODS: Between 1989 and 2001, 40 (22 M/18 F) previously untreated patients with a median age of 5.5 years (3 months-15 years), of histologically proven ependymal tumors (except ependymoblastomas) were referred to the Institute of Oncology, University of Istanbul.
  • Total tumor resection was performed in 20 patients (50%), subtotal in 18 patients (45%), and biopsy only in 2 patients (5%).
  • CONCLUSIONS: The majority of complete responders were patients who had total tumor removal.
  • The median age at diagnosis is 6 years in our patient group; younger children (less than 3 years old) have less favorable outcome.
  • [MeSH-major] Brain Neoplasms. Ependymoma

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 Wiley-Liss, Inc.
  • (PMID = 15770637.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. A da Fonseca M, Thikkurissy S: Maxillary melanotic neuroectodermal tumor of infancy. Int J Clin Pediatr Dent; 2009 Sep;2(3):61-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Maxillary melanotic neuroectodermal tumor of infancy.
  • The melanotic neuroectodermal tumor of infancy (MNTI) is a rare benign neoplasm of neural crest origin most commonly found in the anterior region of the maxilla.
  • The tumor almost always develops during the first year of life, although in some cases it can be present at birth.
  • Main sites for recurrences are the maxilla (57%) and the skull/brain (28.6%).
  • Malignant transformation has been noted in approximately 6.5% of all cases and in 2% of maxillary tumors.
  • The diagnostic and clinico-pathological features as well as tumor management and importance of a timely diagnosis are reviewed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25206125.001).
  • [ISSN] 0974-7052
  • [Journal-full-title] International journal of clinical pediatric dentistry
  • [ISO-abbreviation] Int J Clin Pediatr Dent
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC4086571
  • [Keywords] NOTNLM ; Melanotic neuroectodermal tumor of infancy / maxilla / pediatric dentistry / pediatric oral pathology.
  •  go-up   go-down


92. Zimmermann FB, Geinitz H, Schill S, Thamm R, Nieder C, Schratzenstaller U, Molls M: Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol; 2006;45(7):796-801
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Staging procedures were thoracic and abdominal CT-scan, FDG-PET and CT or MRI of the brain in all patients.
  • Clinical target volume was the tumor as seen in lung windowing of CT and in FDG-PET.
  • We observed four (6%) local tumor recurrences, resulting in an actuarial local tumor control rate of 96%, 88% and 88% after 1, 2 and 3 year follow-up.
  • Nineteen patients died, with eight patients due to cancer (12%), two to local tumor progression alone.
  • Late effects were pneumonitis III degrees in 1%, rib fractures in 3%, and benign pleural effusion in 2 patients.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Dose Fractionation. Lung Neoplasms / surgery. Radiosurgery / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Disease-Free Survival. Fluorodeoxyglucose F18. Humans. Middle Aged. Neoplasm Recurrence, Local / mortality. Neoplasm Recurrence, Local / surgery. Positron-Emission Tomography / methods. Radiation Injuries / diagnosis. Radiation Injuries / epidemiology. Radiotherapy Dosage. Survival Analysis


93. Sun FH, Piao YS, Wang W, Chen L, Wei LF, Yang H, Lu DH: [Brain tumors in patients with intractable epilepsy: a clinicopathologic study of 35 cases]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):153-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brain tumors in patients with intractable epilepsy: a clinicopathologic study of 35 cases].
  • OBJECTIVE: To study the clinicopathologic features of brain tumors occurring in patients with medically intractable epilepsy.
  • METHODS: The clinical, radiologic and pathologic features of brain tumors occurring in 35 patients with intractable epilepsy encountered during the period from January, 2005 to April, 2008 in Xuanwu Hospital were retrospectively reviewed.
  • The histologic types of brain tumors included ganglioglioma (13/35, WHO grade I and 6/35, WHO grade II), dysembryoplastic neuroepithelial tumor (3/35, WHO grade I), pleomorphic xanthoastrocytoma (3/35, WHO grade II), diffuse astrocytoma (1/35, WHO grade II), oligoastrocytoma (1/35, WHO grade II), angiocentric glioma (1/35, WHO grade I) and meningioangiomatosis (1/35).
  • The 6 remaining cases showed features seen in between glioneuronal hamartoma and mixed neuronal-glial tumor.
  • Most of these tumors were located in the temporal lobe (27/35) and associated with focal cortical dysplasia.
  • CONCLUSIONS: Brain tumors in patients with medically intractable epilepsy are almost always benign and located in the temporal lobe.
  • Most of them represent mixed neuronal-glial tumors and some show transitional features in-between glioneuronal hamartoma and mixed neuronal-glial neoplasm.
  • The similar morphologic pattern and biological behavior of glioneuronal hamartoma and mixed neuronal-glial tumor may suggest a common pathogenetic mechanism.
  • [MeSH-major] Brain Neoplasms / complications. Epilepsy / etiology. Glioma / complications
  • [MeSH-minor] Adolescent. Adult. Antigens, CD34 / metabolism. Astrocytoma / complications. Astrocytoma / metabolism. Astrocytoma / pathology. Brain Diseases / complications. Brain Diseases / metabolism. Brain Diseases / pathology. Child. Child, Preschool. Female. Ganglioglioma / complications. Ganglioglioma / metabolism. Ganglioglioma / pathology. Hamartoma / complications. Hamartoma / metabolism. Hamartoma / pathology. Humans. Infant. Magnetic Resonance Imaging. Male. Oligodendroglioma / complications. Oligodendroglioma / metabolism. Oligodendroglioma / pathology. Retrospective Studies. Temporal Lobe / pathology. Young Adult

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575848.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


94. Agrawal A, Kakani A, Vagh SJ, Hiwale KM, Kolte G: Cystic hemangioblastoma of the brainstem. J Neurosci Rural Pract; 2010 Jan;1(1):20-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hemangioblastomas are very highly vascular neoplasm with benign characteristics and; in comparison to cerebellar hemangioblastoma; cases of cystic hemangioblastoma of the brain stem are rare with only a few case reports available in the literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 2003 Jan;98(1):95-105 [12546357.001]
  • [Cites] Rev Neurol. 2009 May 1-15;48(9):463-8 [19396763.001]
  • [Cites] Surg Neurol. 1978 Jun;9(6):337-41 [566959.001]
  • [Cites] Surg Neurol. 1980 Jun;13(6):423-7 [7191146.001]
  • [Cites] Surg Neurol. 1986 Jan;25(1):97-100 [3484562.001]
  • [Cites] J Neurosurg. 1986 Feb;64(2):317-21 [3944644.001]
  • [Cites] Neurochirurgia (Stuttg). 1986 Nov;29(6):230-4 [3808160.001]
  • [Cites] Surg Neurol. 1993 Jan;39(1):25-30 [8451715.001]
  • [Cites] Neurosurg Rev. 1996;19(3):147-51 [8875501.001]
  • [Cites] No Shinkei Geka. 1996 Oct;24(10):949-53 [8914156.001]
  • [Cites] Neurol Med Chir (Tokyo). 1998 Aug;38(8):489-98 [9780648.001]
  • [Cites] Surg Neurol. 2005 Apr;63(4):307-15; discussion 315-6 [15808704.001]
  • [Cites] Neurol India. 2006 Sep;54(3):276-8 [16936388.001]
  • [Cites] Rev Neurol. 2008 Aug 1-15;47(3):134-6 [18654967.001]
  • [Cites] Radiology. 1972 May;103(2):323-8 [5063428.001]
  • (PMID = 21799613.001).
  • [ISSN] 0976-3155
  • [Journal-full-title] Journal of neurosciences in rural practice
  • [ISO-abbreviation] J Neurosci Rural Pract
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3137827
  • [Keywords] NOTNLM ; Cystic hemangioblastoma / fourth ventricle / hemangioblastoma / medulla oblongata
  •  go-up   go-down


95. Crabtree KL, Arnold PM: Spinal seeding of a pilocytic astrocytoma in an adult, initially diagnosed 18 years previously. Pediatr Neurosurg; 2010;46(1):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pilocytic astrocytoma (PA) is a slow-growing, well-circumscribed grade I glioma generally considered benign, with a low recurrence rate and an excellent prognosis following complete surgical resection.
  • To our knowledge, this is the longest time reported from initial tumor resection of leptomeningeal dissemination to the distal spinal cord.
  • PA patients with subtotal resection may benefit from continued follow-up for up to 20 years after the initial diagnosis and resection.
  • [MeSH-major] Astrocytoma / secondary. Brain Neoplasms / pathology. Meningeal Neoplasms / secondary. Neoplasm Seeding. Spinal Cord Neoplasms / secondary

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 S. Karger AG, Basel.
  • (PMID = 20516744.001).
  • [ISSN] 1423-0305
  • [Journal-full-title] Pediatric neurosurgery
  • [ISO-abbreviation] Pediatr Neurosurg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


96. Hourani R, Horská A, Albayram S, Brant LJ, Melhem E, Cohen KJ, Burger PC, Weingart JD, Carson B, Wharam MD, Barker PB: Proton magnetic resonance spectroscopic imaging to differentiate between nonneoplastic lesions and brain tumors in children. J Magn Reson Imaging; 2006 Feb;23(2):99-107
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton magnetic resonance spectroscopic imaging to differentiate between nonneoplastic lesions and brain tumors in children.
  • PURPOSE: To investigate whether in vivo proton magnetic resonance spectroscopic imaging (MRSI) can differentiate between 1) tumors and nonneoplastic brain lesions, and 2) high- and low-grade tumors in children.
  • MATERIALS AND METHODS: Thirty-two children (20 males and 12 females, mean age = 10 +/- 5 years) with primary brain lesions were evaluated retrospectively.
  • Nineteen patients had a neuropathologically confirmed brain tumor, and 13 patients had a benign lesion.
  • Ratios of N-acetyl aspartate/choline (NAA/Cho), NAA/creatine (Cr), and Cho/Cr were evaluated in the lesion and the contralateral hemisphere.
  • RESULTS: Considering all possible combinations of metabolite ratios, the best discriminant function to differentiate between nonneoplastic lesions and brain tumors was found to include only the ratio of Cho/Cr (Wilks' lambda, P = 0.012; 78.1% of original grouped cases correctly classified).
  • The best discriminant function to differentiate between high- and low-grade tumors included the ratios of NAA/Cr and Cho(norm) (Wilks' lambda, P = 0.001; 89.5% of original grouped cases correctly classified).
  • Cr levels in low-grade tumors were slightly lower than or comparable to control regions and ranged from 53% to 165% of the control values in high-grade tumors.
  • CONCLUSION: Proton MRSI may have a promising role in differentiating pediatric brain lesions, and an important diagnostic value, particularly for inoperable or inaccessible lesions.
  • [MeSH-major] Astrocytoma / diagnosis. Brain Neoplasms / diagnosis. Germinoma / diagnosis. Glioma / diagnosis. Magnetic Resonance Spectroscopy / methods
  • [MeSH-minor] Adolescent. Biopsy, Needle. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Neoplasm Staging. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Published 2005 Wiley-Liss, Inc.
  • (PMID = 16374884.001).
  • [ISSN] 1053-1807
  • [Journal-full-title] Journal of magnetic resonance imaging : JMRI
  • [ISO-abbreviation] J Magn Reson Imaging
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS042851; United States / NCRR NIH HHS / RR / P41RR15241
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


97. Zhou J, Li NY, Zhou XJ, Zhou HB, Wu B, Jiang SJ, Ma HH, Zhang RS: [Clinicopathologic study of von Hippel-Lindau syndrome-related and sporadic hemangioblastomas of central nervous system]. Zhonghua Bing Li Xue Za Zhi; 2010 Mar;39(3):145-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study clinicopathologic features, diagnosis, treatment and prognosis of von Hippel-Lindau (VHL) syndrome-related and sporadic hemangioblastomas of the central nervous system (CNS-HB).
  • There were 10 patients presenting other lesions related to VHL, including 6 retinal HBs, 4 pancreatic tumors (endocrine tumor and microcystic cystadenoma), 1 clear renal cell carcinoma, 4 renal cysts and 1 endolymphatic sac tumor.
  • One patient developed 5 different tumors related to VHL within a period of 4 years.
  • Histologically, the tumors showed large and vacuolated stromal cells.
  • Some tumors showed atypical nuclei.
  • Involvement of the brain tissue was seen in 32 cases, among which, 21 patients with available follow-up information were learnt to be alive.
  • Tumor cells of HB stained positive for vimentin, EGFR, Inhibin alpha and D2-40, but negative for CD34 and CD68.
  • CONCLUSIONS: VHL syndrome is a multisystem disorder with a poor prognosis and a high rate of missed diagnosis.
  • The syndrome is characterized by development of various benign and malignant tumors.
  • The most common tumor is CNS-HB, which occurs predominantly in the cerebellum.
  • Patients with VHL syndrome tend to present at a younger age than patients with sporadic CNS-HBs, and VHL related HB occurs more predominantly in the brain stem and spinal cord.
  • Prognosis of CNS-HB patients is not correlated with the nuclear atypicality, expression for Ki-67 and involvement of the brain tissue.
  • [MeSH-major] Central Nervous System Neoplasms / pathology. Hemangioblastoma / pathology. von Hippel-Lindau Disease / pathology
  • [MeSH-minor] Adolescent. Adult. Carcinoma, Renal Cell / metabolism. Carcinoma, Renal Cell / pathology. Carcinoma, Renal Cell / surgery. Child. Female. Follow-Up Studies. Glial Fibrillary Acidic Protein / metabolism. Humans. Inhibins / metabolism. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Receptor, Epidermal Growth Factor / metabolism. Retinal Neoplasms / metabolism. Retinal Neoplasms / pathology. Retinal Neoplasms / surgery. Survival Analysis. Vimentin / metabolism. Young Adult

  • Genetic Alliance. consumer health - Von Hippel-Lindau syndrome.
  • MedlinePlus Health Information. consumer health - Von Hippel-Lindau Disease.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20450758.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Glial Fibrillary Acidic Protein; 0 / Ki-67 Antigen; 0 / Vimentin; 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


98. Shrieve DC: Basic principles of radiobiology applied to radiotherapy of benign intracranial tumors. Neurosurg Clin N Am; 2006 Apr;17(2):67-78, v
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Basic principles of radiobiology applied to radiotherapy of benign intracranial tumors.
  • The use of ionizing radiation in the treatment of benign intracranial tumors may involve one of several types of ionizing radiation given as single-fraction radiosurgery or fractionated radiotherapy.
  • This article discusses the basic radiobiologic principles applicable to radiotherapy of benign brain tumors.
  • [MeSH-major] Brain / radiation effects. Brain Neoplasms / radiotherapy. Radiobiology / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16793500.001).
  • [ISSN] 1042-3680
  • [Journal-full-title] Neurosurgery clinics of North America
  • [ISO-abbreviation] Neurosurg. Clin. N. Am.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Regelsberger J, Hagel C, Emami P, Ries T, Heese O, Westphal M: Secretory meningiomas: a benign subgroup causing life-threatening complications. Neuro Oncol; 2009 Dec;11(6):819-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretory meningiomas: a benign subgroup causing life-threatening complications.
  • While meningiomas are known as slow-growing extracerebral neoplasms, the subgroup of secretory meningiomas with histologically benign characteristics tend to cause disproportional peritumoral edema, frequently leading to severe medical and neurological complications in postoperative management.
  • Among 1,484 meningiomas that were resected at our institution between 1990 and 2007, 44 (3%) patients were found to have the histological diagnosis of a secretory meningioma.
  • The clinical course, radiological appearance, and histopathological features were retrospectively analyzed to examine the specifics of these benign lesions.
  • A severe, nearly hemispheric perifocal edema disproportional to tumor size was seen on preoperative MR imaging in 18 (41%) patients.
  • An association between the extent of brain edema and number of periodic acid Schiff-positive pseudopsammomas was found (p < 0.02).
  • Mean MIB-1 (Ki-67 antigen) proliferation index was 3.0% (range, 0%-17%) and did not correlate with edema or tumor recurrence.
  • [MeSH-major] Brain Edema / etiology. Meningeal Neoplasms / complications. Meningeal Neoplasms / metabolism. Meningioma / complications. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / metabolism. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Keratins / metabolism. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / metabolism. Neoplasm Staging. Prognosis. Retrospective Studies. Tomography, X-Ray Computed

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Clin Path. 1999 Jul;3(3):47-53 [10655573.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):297-301; discussion 301-2 [11220371.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:19-21 [11386820.001]
  • [Cites] J Clin Neurosci. 2001 Jul;8(4):335-9 [11437574.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):765-72 [11857311.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):590-8 [12152157.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):353-7 [17721284.001]
  • [Cites] Am J Surg Pathol. 1986 Feb;10(2):102-11 [2420220.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 1989 Dec;18(4):287-9 [2636960.001]
  • [Cites] Histopathology. 1992 Nov;21(5):475-7 [1452131.001]
  • [Cites] Cancer. 1997 May 15;79(10):2003-15 [9149029.001]
  • [Cites] Neurosurg Rev. 2006 Jan;29(1):41-8 [16010579.001]
  • [Cites] Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 May;37(3):488-91 [16761441.001]
  • [Cites] J Neurooncol. 2003 May;62(3):233-41 [12777074.001]
  • (PMID = 19066343.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Ki-67 Antigen; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC2802401
  •  go-up   go-down


100. Kernick D, Stapley S, Goadsby PJ, Hamilton W: What happens to new-onset headache presented to primary care? A case-cohort study using electronic primary care records. Cephalalgia; 2008 Nov;28(11):1188-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Records of patients who presented with primary headache (migraine, tension-type headache, cluster headache) or undifferentiated headache (no further descriptor) were examined for the subsequent year for subarachnoid haemorrhage, primary brain tumour, benign space-occupying lesion, temporal arteritis, stroke and transient ischaemic attack.
  • The 1-year risk of a malignant brain tumour with new undifferentiated headache was 0.15%, rising to 0.28% above the age of 50 years.
  • The risk for a benign space-occupying lesion was 0.05% for an undifferentiated and 0.009% for a primary headache.
  • Accepting the limitations of this approach, our data can inform management guidelines for new presentations of headache in primary care and confirm the need for follow-up, even if a primary headache diagnosis is made.
  • [MeSH-major] Headache / diagnosis. Headache / epidemiology. Headache / etiology
  • [MeSH-minor] Adult. Brain Diseases / complications. Case-Control Studies. Female. Humans. Male. Middle Aged. Primary Health Care

  • MedlinePlus Health Information. consumer health - Headache.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Headache. 2011 Feb;51(2):346-52 [21284622.001]
  • (PMID = 18771496.001).
  • [ISSN] 1468-2982
  • [Journal-full-title] Cephalalgia : an international journal of headache
  • [ISO-abbreviation] Cephalalgia
  • [Language] eng
  • [Grant] United Kingdom / Department of Health / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down






Advertisement